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Direct cardiac reprogramming is a promising approach to cardiac regeneration. Fibroblasts are 
converted directly into induced cardiomyocytes (iCMs) in vitro and in vivo through exogenous expression 
of three cardiac lineage transcription factors – Gata4, Mef2c, and Tbx5. Before direct cardiac 
reprogramming is ready to be deployed as a clinical therapy, however, additional research is required to 
improve the efficiency of the reprogramming process and the purity and maturity of the generated 
iCMs. Our work provides new insight into epigenetic regulation of reprogramming induction and 
molecular mechanisms of cell fate conversion to increase reprogramming efficiency and maturation. We 
first developed a series of cell lines as tools for ongoing research. We developed an αMHC-GFP cardiac 
reporter fibroblast cell line for convenient reprogramming and rapid detection of newly derived iCMs. 
Additionally, we generated a tetracycline inducible polycistronic reprogramming factor construct for the 
temporal regulation of the reprogramming cocktail. We introduced this construct into our cell line to 
create an inducibly reprogrammable fibroblast cell line. These cell lines have enabled large-scale screens 
of potential regulatory factors. We next explored the epigenetic regulation of early-stage 
reprogramming events to increase the efficiency of the reprogramming process. Preliminary data from 
the Qian lab implicated chromatin remodeling complexes as epigenetic barriers in transcription factor 
mediated direct cardiac reprogramming. We explored the role of the Polycomb Repressive Complex 1 
(PCR1) and 2 (PCR2) in reprogramming and found that while inhibiting PRC2 activity did not increase 
reprogramming, inhibiting PCR1 member Bmi1 significantly enhanced reprogramming efficiency. Bmi1 
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depletion de-represses endogenous Gata4 expression and effectively replaces exogenous Gata4 
expression from the reprogramming cocktail. Finally, we describe a novel mitochondrial mechanism 
regulating iCM reprogramming efficiency and maturation. Inhibiting mitochondrial fission by depleting 
Fis1 enhances the efficiency of direct cardiac reprogramming and increases mitochondrial quantity and 
respiratory capacity. Overexpression of PGC1α to drive mitochondrial biogenesis similarly enhances 
reprogramming, confirming that the effect on reprogramming is due to increased mitochondrial content 
in reprogramming cells. Additional studies are needed to elucidate the mechanism by which Fis1 
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CHAPTER 1: INTRODUCTION1 
Introduction 
As the leading cause of death in the United States, heart disease accounts for one out of every 
four mortalities (cdc.gov, 2016a). Contributing to this, every year 735,000 Americans experience a 
myocardial infarction (cdc.gov, 2016b) which reduces the heart’s pump capacity due to cardiomyocyte 
death and increases the risk of arrhythmia from the deposition of non-conductive scar tissue. There are 
currently three primary approaches to cardiac regeneration as a therapy for myocardial infarction: 1) 
progenitor cell transplantation, 2) induced proliferation of resident cardiomyocytes, and 3) non-myocyte 
cell fate reprogramming. The first, progenitor cell therapy, is limited by the low viability and integration 
of transplanted cells. Multiple clinical trials have demonstrated that the engraftment rate of 
transplanted cells and the number of cardiomyocytes derived from transplanted progenitors are 
insufficient to produce a therapeutic effect (Lin and Pu, 2014). However, some clinical benefit is 
observed due to paracrine signaling from the transplanted progenitors (Lin and Pu, 2014). Identification 
of the contributing factors will produce the same effect while bypassing transplantation altogether (Lin 
and Pu, 2014). The second approach, inducing myocyte cell cycle re-entry, is accompanied by both 
efficacy and safety concerns. Studies have yet to demonstrate that the proposed methods for 
stimulating cardiomyocyte proliferation can generate a sufficient quantity of new cardiomyocytes to 
produce a clinically relevant effect (Lin and Pu, 2014). Furthermore, induced proliferation approaches 
must demonstrate cardiomyocyte-selective stimulation to preclude oncogenesis (Lin and Pu, 2014). The 
third approach, cell fate reprogramming of endogenous non-myocytes, is addressed in this review.  
 
1 Chapter 1 was published as a review paper in Protein & Cell. Its formal citation is: Vaseghi, H., Liu, J., and Qian, L. 
(2017). Molecular barriers to direct cardiac reprogramming. Protein Cell 8, 724–734. 
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Cell fate reprogramming confers a dual advantage of reducing scar tissue while simultaneously 
generating new cardiomyocytes. Following coronary artery ligation, direct cardiac reprogramming 
reduces scar size in murine hearts by over two-fold (Qian et al., 2012; Song et al., 2012). New fibroblast-
derived reprogrammed cardiomyocytes comprise 35% of cardiomyocytes in the infarct and border zones 
(Qian et al., 2012). These newly reprogrammed cardiomyocytes exhibit integration into the working 
myocardium, with electrical connectivity to endogenous cardiomyocytes and coordinated contraction 
(Qian et al., 2012; Song et al., 2012). Concomitant with measurably reducing scar size and generating 
new cardiomyocytes, direct cardiac reprogramming demonstrates substantial therapeutic benefit. 
Reprogramming therapy improves ejection fraction, stroke volume, and cardiac output in murine hearts 
following coronary artery ligation (Qian et al., 2012; Song et al., 2012) and sustains improvement up to 
12 weeks after myocardial infarction (Song et al., 2012), demonstrating its potential as a therapeutic 
approach. With the in situ regeneration of mature, functional cardiomyocytes and simultaneous 
reduction in scar tissue, direct cardiac reprogramming has strong potential as a clinical therapy to 
restore cardiac function following myocardial infarction. Although significant advances have been made, 
studies have uncovered numerous molecular barriers to the reprogramming process. This review 
explores the molecular barriers to cell fate conversion in order to facilitate effective and complete direct 
cardiac reprogramming. 
Reprogramming Factor Cocktails 
Observation that only a fraction of the starting cell population fully reprograms into functional 
cardiomyocytes has prompted numerous initiatives to screen candidate reprogramming factors in order 
to identify cocktails for optimal reprogramming efficiency. Studies have screened cocktails of 
transcription factors (Addis et al., 2013; Christoforou et al., 2013; Ieda et al., 2010; Protze et al., 2012; 
Song et al., 2012), microRNAs (Jayawardena et al., 2012, 2015), small molecules (Fu et al., 2015, 2015; 
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Mohamed et al., 2016), and combinations of the three (Ifkovits et al., 2014; Muraoka et al., 2014; Wang 
et al., 2014). 
Direct cardiac reprogramming was first described using a transcription factor cocktail. Ieda et al. 
screened a pool of fourteen cardiac lineage transcription factors to define a cocktail of three 
reprogramming factors – Gata4, Mef2c, and Tbx5 (GMT) – that are necessary and sufficient to convert 
fibroblasts to induced cardiomyocyte-like cells (iCMs) both in vitro (Ieda et al., 2010; Wang et al., 2015a) 
and in vivo (Inagawa et al., 2012; Ma et al., 2015; Qian et al., 2012). Subsequently, Song et al. screened 
six conserved cardiac lineage transcription factors to identify a cocktail of Gata4, Hand2, Mef2c, and 
Tbx5 (GHMT) that generates almost five-fold more cTnT/αMHC-GFP double positive iCMs than GMT in 
vitro (Song et al., 2012). The GHMT cocktail also generates iCMs in murine hearts in vivo, reducing scar 
size and improving cardiac function following myocardial infarction (Song et al., 2012). While the above 
mentioned studies employed sequential subtraction of candidate factors and αMHC-GFP reporter 
expression to screen cocktails, Protze et al. tested all possible triplet combinations of ten 
reprogramming factors and used quantitate PCR for multiple cardiac markers to identify a three factor 
reprogramming cocktail of Mef2c, Tbx5, and Myocd that induces expression of a broad range of cardiac 
genes (Protze et al., 2012). Christoforou et al. furthermore demonstrated that a five or a seven factor 
cocktail adding Myocd, SRF, Mesp1, and SMARCD3 to the three factor GMT cocktail enhances cTnT 
mRNA expression by almost five-fold (Christoforou et al., 2013). Finally, Addis et al. employed a calcium 
reporter to functionally screen candidate factors and define a five factor cocktail of Hand2, Nkx2.5, 
Gata4, Mef2c, and Tbx5 (HNGMT) for maximally efficient reprogramming of functional iCMs (Addis et 
al., 2013).  
In addition to transcription factor cocktails, microRNA combinations successfully generate 
reprogrammed iCMs. Jayawardena et al. screened six candidate microRNAs selected for their regulatory 
role in cardiomyocyte differentiation and development, transfecting cardiac fibroblasts with all 41 
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permutations of singlet, doublet, and triplet microRNA combinations and screening using quantitative 
PCR for cardiac markers (Jayawardena et al., 2012). A cocktail of miR-1, miR-133, miR-208, and miR-499 
is sufficient to reprogram cardiac fibroblasts both in vitro (Jayawardena et al., 2012) and in vivo 
(Jayawardena et al., 2015). The microRNA cocktail generates functional, mature iCMs in vivo and 
reduces scar size and improves cardiac function in murine hearts following myocardial infarction 
(Jayawardena et al., 2015). The mechanism of miR-1 and miR-133 enhancement of reprogramming is 
discussed below in the section “Repression of Fibroblast Identity”.  
Chemical cocktails for direct cardiac reprogramming have also been developed, circumventing 
the genetic manipulation associated risks involved in transcription factor and microRNA cocktails. Fu et 
al. noted the emergence of spontaneously beating cells during iPSC reprogramming using a cocktail of 
small molecule compounds and developed a two-step reprogramming process to induce and stabilize 
iCM reprogramming (Fu et al., 2015). This two-step chemical cocktail reprogramming generates beating 
clusters of iCMs that express cardiac markers, assemble contractile sarcomeres, and display 
cardiomyocyte-like electrophysical properties without going through a pluripotent stage (Fu et al., 
2015).  
In addition to pure cocktails of transcription factors, microRNA, or small molecules, 
combinations of factors produce a synergistic effect for maximal reprogramming efficiency. Wang et al. 
directly reprogrammed fibroblasts into iCMs without going through a pluripotent intermediate state 
using a chemical cocktail plus a single transcription factor Oct4 (Wang et al., 2014). Conversely, Ifkovits 
et al. used a single small molecule TGFβ inhibitor to enhance reprogramming efficiency of the 
transcription factor cocktail HNGMT by five-fold (Ifkovits et al., 2014). Mohamed et al. found that WNT 
and TGFβ inhibitors enhance GMT transcription factor cocktail reprogramming by eight-fold (Mohamed 
et al., 2016). The effects of TGFβ and WNT signaling in reprogramming are discussed below in the 
sections “Repression of Fibroblast Identity” and “Intracellular Signaling Pathways”. Muraoka et al. found 
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that miR-1 or miR-133 together with the transcription factor cocktail GMT produced a six-fold increase 
over GMT alone (Muraoka et al., 2014). The mechanism of miR-1 and miR-133 enhancement of 
reprogramming is also discussed below in the section “Repression of Fibroblast Identity”. Jayawardena 
et al. used a small molecule compound, JAK inhibitor I, in combination with the micoRNA cocktail miR-1, 
miR-133, miR-208, and miR-499 to increase reprogramming efficiency by ten-fold (Jayawardena et al., 
2012). 
Reprogramming Factor Stoichiometry 
Decades of research in developmental biology have revealed the fine balance of transcription 
factor expression that is required to initiate and maintain cardiac lineage commitment. However, in cell 
fate reprogramming, the forced overexpression of reprogramming factors results in crude, artificial 
transcription factor dosage. Most studies using the standard Gata4, Mef2c, Tbx5 cocktail utilize 
retroviral delivery of the three factors packaged as separate viruses. Starting cells must take up each of 
the three individual viruses in order to be reprogrammed, leading to low cell fate conversion rates since 
only a subset of cells receive all three factors. Individual cells also receive different ratios of the three 
factors. Stochastically, only a small fraction of cells receives the optimal reprogramming factor ratio and 
dose for cell fate reprogramming. 
To address reprogramming factor stoichiometry, our lab determined the optimal ratio of the 
three transcription factors for efficient reprogramming by creating six polycistronic constructs with the 
three factors in every possible splice order separated by 2A peptide cleavage sites (Wang et al., 2015a). 
Splice order dictates protein expression level, with highest protein expression for the factor in the first 
position and lower protein expression for the factors in the second and third positions (Wang et al., 
2015a). Only the Mef2c-Gata4-Tbx5 (MGT) and Mef2c-Tbx5-Gata4 (MTG) constructs, which have Mef2c 
in the first position, increase reprogramming efficiency compared to infection with three separate 
Gata4, Mef2c, and Tbx5 viruses (Wang et al., 2015a). The other four constructs decreased αMHC-GFP 
6 
iCM reporter expression compared to reprogramming with separate viruses (Wang et al., 2015a). The 
highest reporter expression was achieved using the MGT splice order with concomitantly higher levels of 
Mef2c and lower levels of Gata4 and Tbx5 (Wang et al., 2015a). The optimal polycistronic MGT vector 
improved both MHC-GFP reporter expression and cTnT cardiac marker expression compared to 
separate Gata4, Mef2c, Tbx5 virus reprogramming (Wang et al., 2015a). The polycistronic MGT vector 
generated reprogrammed cells that formed iCM clusters, assembled cTnT and -Actinin positive 
sarcomeres, expressed the gap junction protein Connexin 43, exhibited calcium flux, and contracted 
spontaneously (Wang et al., 2015a). Molecular characterization also shows that the MGT and MTG 
polycistronic vectors induce higher expression of cardiomyocyte genes and lower expression of cardiac 
stress genes Nppa and Nppb than reprogramming with separate viruses (Wang et al., 2015a). An 
optimized protocol for reprogramming using the polycistronic MGT system was described as an 
additional resource (Wang et al., 2015b). 
We also demonstrated that optimal reprogramming factor stoichiometry using the polycistronic 
MGT vector improves reprogramming efficiency in vivo in a mouse model of myocardial infarction (Ma 
et al., 2015). Using Periostin-Cre; R26R-lacZ genetic lineage tracing, cells of fibroblast origin were 
irreversibly marked with -galactosidase to identify iCMs generated from fibroblasts (Ma et al., 2015). In 
vivo reprogramming with polycistronic MGT following coronary artery ligation increases the number of 
-Actinin/-galactosidase double positive iCMs compared to reprogramming with separate Gata4, 
Mef2c, Tbx5 viruses (Ma et al., 2015). Additionally, in vivo reprogramming with the polycistronic MGT 
vector produces greater functional improvement in fractional shortening and ejection fraction and 
reduces scar size following myocardial infarction than reprogramming with separate viruses (Ma et al., 
2015). Optimal stoichiometry of the three transcription factors using a polycistronic vector increases the 
efficiency of in vivo reprogramming and further improves cardiac function following myocardial 
infarction (Ma et al., 2015). 
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In addition to defining the optimal reprogramming factor stoichiometry, we created an inducible 
system where polycistronic MGT expression is both temporally and quantitatively regulated through the 
administration of doxycycline (Vaseghi et al., 2016). Using the TetOn inducible gene expression system, 
reprogramming factor expression is tightly regulated by the presence of doxycycline in the cell culture 
media (Vaseghi et al., 2016). Additionally, by titrating the doxycycline concentration, reprogramming 
factor expression level and dosage can be controlled (Vaseghi et al., 2016). 
Two other in vivo studies also created polycistronic reprogramming vectors. Inagawa et al. 
placed the reprogramming factors in the order Tbx5-Mef2c-Gata4 (Inagawa et al., 2012), while Mathison 
et al. used the order Gata4-Mef2c-Tbx5 (Mathison et al., 2014). Both studies demonstrate a modest 
increase in reprogramming efficiency using their single polycistronic vector compared to three separate 
viruses, but the improvement is only incremental due to the non-optimal dosage of the reprogramming 
factors. Inagawa et al. found no difference in the proportion of -Actinin positive reprogrammed cells to 
infected cells between their polycistronic TMG vector and separate viruses but did see the proportion of 
-Actinin positive cells that had assembled sarcomeres double from 15% to 30% of infected cells 
(Inagawa et al., 2012). Mathison et al. demonstrated increased numbers of reprogrammed cells in vitro 
and improved cardiac function in vivo using their GMT polycistronic vector (Mathison et al., 2014).  The 
incremental improvement demonstrated by these polycistronic systems is possibly due to the increased 
delivery of all three reprogramming factors to the starting cell population, although the optimal dosage 
of the reprogramming factors was not considered. 
Epigenetic Barriers to Direct Cardiac Reprogramming 
In addition to reprogramming factor dosage and timing, the epigenetic regulation of gene 
expression programs is critical to cell lineage commitment. Highlighting the role of epigenetic 
modulation in cell fate determination and conversion, Takeuchi and Bruneau directed ectopic 
differentiation of embryonic mouse mesoderm into beating cardiomyocytes using transient transfection 
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of the cardiac transcription factor Gata4 and the cardiac specific chromatin remodeling complex subunit, 
Baf60c (Takeuchi and Bruneau, 2009). Baf60c potentiates the binding of Gata4 to DNA at cardiac loci to 
turn on ectopic cardiac gene expression (Takeuchi and Bruneau, 2009). Transfection of the transcription 
factor Tbx5 in addition to Gata4 and Baf60c promotes the complete differentiation of transfected cells 
into beating cardiomyocytes (Takeuchi and Bruneau, 2009). The transfected cells begin beating even 
before the endogenous heart field starts to form(Takeuchi and Bruneau, 2009). Baf60c is one of the 
minimal requirements for this ectopic cardiac differentiation of the embryonic mesoderm, 
demonstrating that chromatin remodeling plays a crucial role in transdifferentiation and cardiac fate 
acquisition. Cellular reprogramming necessarily involves changes to the epigenetic landscape. Epigenetic 
marks must be erased and re-written to alter chromatin structure and gene expression patterns during 
reprogramming as the fibroblast signature is repressed and a cardiomyocyte gene expression program is 
activated. Recent studies have demonstrated that epigenetic manipulation can potentiate the 
reprogramming process. 
Epigenetic regulation of gene transcription is mediated through histone post-translational 
modification, including histone acetylation. Studies in cardiac development suggest that histone 
deacetylase (HDAC) inhibition directs cells toward a cardiac lineage fate (Chen et al., 2011a; 
Karamboulas et al., 2006). Overexpression of HDAC4, a class IIa HDAC, inhibits cardiac muscle 
development, while class IIa HDAC inhibition restores cardiomyogenesis (Karamboulas et al., 2006). 
Commitment to the cardiac lineage is accompanied by the upregulation of Gata4, Mef2c, and other key 
cardiac transcription factors (Karamboulas et al., 2006); however, Class IIa HDACs repress cardiac 
transcription factors, including Gata4 and Mef2 family transcription factors (McKinsey and Olson, 2004; 
Miska et al., 1999). Consequently, HDAC inhibition promotes cardiomyogenesis and upregulates the 
expression of cardiac transcription factors Gata4, Mef2c, and Nkx2.5, among others (Chen et al., 2011a).  
Simultaneous induction of reprogramming factor expression and HDAC inhibition using valproic acid, a 
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non-specific HDAC inhibitor, enhances direct cardiac reprogramming, increasing the proportion of cTnT 
or -Actinin positive reprogrammed cells by two-fold (Christoforou et al., 2013). These findings suggest 
that HDAC inhibition may enhance direct cardiac reprogramming by epigenetically priming cells for 
cardiac fate acquisition. 
Widespread epigenetic repatterning occurs during direct cardiac reprogramming. Zhao et al. 
performed chromatin immunoprecipitation sequencing of H3K4me2, which marks the promoters and 
enhancers of transcriptionally active genes, and demonstrated that one week after GHMT cocktail 
reprogramming 47% of the H3K4me2 peaks had shifted to align with those of primary cardiomyocytes 
(Zhao et al., 2015). Our lab demonstrated that trimethylation of lysine 27 on histone 3 (H3K27me3), a 
repressive epigenetic mark, is depleted and trimethylation of lysine 4 on histone 3 (H3K4me3), an 
activating histone modification, is enriched at cardiac promoters early in GMT cocktail reprogramming 
and is accompanied by a rapid increase in cardiac gene mRNA expression (Liu et al., 2016b). This early 
activation of the cardiomyocyte gene expression program is later followed by the increase of H3K27me3 
and decrease of H3K4me3 at fibroblast loci and a concomitant decrease in fibroblast gene mRNA 
expression (Liu et al., 2016b). These findings suggest that reprogramming activates cardiac gene 
expression first, followed by later repression of fibroblast gene expression. Similarly, Dal-Pra et al. 
demonstrated that H3K27 demethylation is required for the induction of cardiac gene expression during 
microRNA cocktail reprogramming (Dal-Pra et al., 2017). Reprogramming with a miR-1, miR-133, miR-
208, miR-499 microRNA cocktail alters H3K27 methyltransferase and demethylase expression, inducing a 
40% and 50% increase in expression of the two H3K27 demethylases Kdm6B and Kdm6A respectively 
and a 50% decrease in expression of the H3K27 methyltransferase Ezh2 at both the mRNA and protein 
level (Dal-Pra et al., 2017). Consequently, reprogramming reduces global H3K27me3 by 40% (Dal-Pra et 
al., 2017). Specifically, promoters of cardiac transcription factors Tbx5, Mef2c, and Gata4 exhibit a 50% 
reduction in H3K27me3 (Dal-Pra et al., 2017). Pharmacologic inhibition of H3K27 methyltransferase 
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activity reduces H3K27me3 by 30% and increases gene and protein expression of cardiac markers 
between two- to eight-fold irrespective of microRNA cocktail reprogramming (Dal-Pra et al., 2017). 
Conversely, knockdown of H3K27 demethylase activity inhibits the induction of cardiac marker 
expression during microRNA cocktail reprogramming (Dal-Pra et al., 2017). These findings demonstrate 
that H3K27 demethylation and de-repression of cardiac loci is essential for direct cardiac 
reprogramming. 
Given that extensive repatterning of histone modifications occurs during the reprogramming 
process, modulation of the deposition and removal of histone modifications may promote greater 
reprogramming efficiency. Hirai et al. used a small molecule inhibitor of Ezh2, the catalytic component 
of the PRC2 complex catalyzing H3K27me2/3, to demonstrate that Ezh2 inhibition early in 
reprogramming increases reprogramming efficiency (Hirai and Kikyo, 2014). The authors also report that 
late inhibition of the methyltransferase G9a, which catalyzes H3K9me1/2, increases reprogramming 
efficiency (Hirai and Kikyo, 2014). Conversely, Ifkovits et al. found that pre-treatment of fibroblasts with 
a G9a histone methyltransferase inhibitor reduced reprogramming efficiency (Ifkovits et al., 2014), 
demonstrating that the timing of histone methyltransferase inhibition is crucial for its effect on 
reprogramming. Hirai et al. observed that only specific time windows of drug administration were 
sufficient to promote an increase in reprogrammed cells and that inhibition at other times resulted in no 
effect or a decrease in reprogramming efficiency (Hirai and Kikyo, 2014). The two histone 
methyltransferases inhibited by Hirai et al., Ezh2 and G9a, require inhibition at different times to 
promote increased reprogramming (Hirai and Kikyo, 2014). While early inhibition of Ezh2 resulted in 
maximal generation of iCM clusters, late inhibition of G9a promoted iCM generation (Hirai and Kikyo, 
2014), indicating that the timing of histone methyltransferase inhibition is critical to enhancing 
reprogramming. 
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To identify key epigenetic barriers to the reprogramming process, we conducted a 
comprehensive loss-of-function screen of epigenetic modifying factors and identified Bmi1 as a critical 
epigenetic inhibitor of reprogramming (Zhou et al., 2016). Bmi1 is a polycomb group protein that 
directly binds to cardiac loci and suppresses expression of cardiac genes (Zhou et al., 2016). Depleting 
Bmi1 increases H3K4me3 and reduces H2AK119ub at cardiac loci and subsequently de-represses cardiac 
gene expression, priming fibroblasts for reprogramming (Zhou et al., 2016). Bmi1 knockdown plays a 
role to enhance cardiac fate acquisition early in the reprogramming process, as late Bmi1 depletion does 
not affect reprogramming (Zhou et al., 2016). Bmi1 also directly binds to the regulatory region and 
modulates the expression of Gata4 (Zhou et al., 2016). The inhibition of Bmi1 de-represses endogenous 
Gata4 expression and can therefore replace exogenous Gata4 in the Gata4, Mef2c, Tbx5 reprogramming 
cocktail (Zhou et al., 2016), permitting two factor-mediated iCM reprogramming to be possible.  
In a similar approach, Liu et al. conducted a gain-of-function screen of cardiac development 
epigenetic modifiers and transcription factors and identified the H3K4 methyltransferase Mll1 as a 
barrier to direct cardiac reprogramming (Liu et al., 2016a). Pharmacologic inhibition of Mll1 improves 
both iCM generation with a 1.5-fold increase in MHC-GFP reporter expression and iCM maturation 
with increased sarcomere assembly and spontaneous beating (Liu et al., 2016a). Inhibition of Mll1 
directs cardiomyocyte cell fate specification by suppressing adipocyte lineage transdifferentiation (Liu et 
al., 2016a). Mll1 inhibition prevents MGT-mediated upregulation of adipocyte genes and adipocyte 
formation as indicated by Oil Red O staining (Liu et al., 2016a). The adipocyte associated gene Ebf1 is a 
key target of Mll1, and the reduction in Ebf1 expression caused by Mll1 inhibition mediates the 
observed increase in reprogramming efficiency (Liu et al., 2016a). 
Repression of Fibroblast Identity 
Direct cardiac reprogramming is accomplished through the activation of cardiac gene expression 
but must also be accompanied by complete silencing of the original fibroblast signature. 
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Characterization of epigenetic repatterning during reprogramming by Liu et al. demonstrates a gradual 
repression of fibroblast loci (Liu et al., 2016b). Chromatin immunoprecipitation followed by real time 
PCR reveals late deposition of the repressive H3K27me3 histone modification at fibroblast marker gene 
promoters and fibroblast-enriched transcription factor promoters with a concomitant decrease in mRNA 
expression (Liu et al., 2016b). 
Maintenance of residual fibroblast gene expression presents a roadblock to the successful 
reprogramming of functionally mature cardiomyocytes. MicroRNAs miR-1 and miR-133 enhance direct 
cardiac reprogramming by suppressing fibrotic gene expression (Muraoka et al., 2014; Zhao et al., 2015). 
Overexpression of miR-1 and miR-133 together with reprogramming cocktails generates more 
spontaneously beating iCMs faster than reprogramming cocktails alone (Muraoka et al., 2014; Zhao et 
al., 2015). Reprogramming with miR-133 also generates more iCMs exhibiting spontaneous calcium 
oscillations than transcription factor cocktails alone (Muraoka et al., 2014). A combination of both miR-1 
and miR-133 with transcription factor reprogramming cocktails was the most efficient treatment for 
generating spontaneously beating iCMs (Zhao et al., 2015). MiR-133 overexpression represses fibroblast 
gene expression through the suppression of Snai1 (Muraoka et al., 2014). Snai1 knockdown suppresses 
fibroblast gene expression and promotes cardiac gene expression in reprogramming, while Snai1 
overexpression maintains fibroblast gene expression and inhibits the development of spontaneous 
beating in iCMs (Muraoka et al., 2014). These studies indicate that microRNA repression of fibroblast 
gene expression improves reprogramming speed and iCM functional maturity. 
In another approach to erasing fibroblast identity, studies have used inhibition of pro-fibrotic 
signaling pathways to enhance reprogramming efficiency (Ifkovits et al., 2014; Zhao et al., 2015). 
Silencing pro-fibrotic transforming growth factor beta (TGF) signaling and Rho-associated kinase 
(ROCK) signaling increases iCM conversion numbers and speed (Ifkovits et al., 2014; Zhao et al., 2015). 
Conversely, overexpression of these pathways inhibits the reprogramming process (Ifkovits et al., 2014; 
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Zhao et al., 2015). Maintenance of pro-fibrotic signaling leads to incompletely converted cells; however, 
reprogramming factor expression is sufficient to activate pro-fibrotic signaling, which must be 
subsequently suppressed for successful conversion (Zhao et al., 2015). Early administration or pre-
treatment with a TGF inhibitor silences pro-fibrotic signaling to enhance reprogramming efficiency 
(Ifkovits et al., 2014; Mohamed et al., 2016). In conjunction with miR-1 and miR-133 overexpression, 
ROCK or TGF inhibition further represses fibroblast gene expression and increases reprogramming 
efficiency and speed, suggesting a synergistic barrier to reprogramming between pro-fibrotic signaling 
and microRNA fibroblast gene regulation (Zhao et al., 2015). Similarly, dual inhibition of TGF and Wnt 
signaling improves the quantity, maturation, and speed of reprogramming (Mohamed et al., 2016). Early 
TGF inhibition followed shortly by Wnt inhibition generates an eight-fold increase in MHC-GFP 
reporter positive iCMs (Mohamed et al., 2016). These iCMs exhibit accelerated reprogramming with 
beating cells observed as early as one week after reprogramming (Mohamed et al., 2016). TGF/Wnt 
inhibition during reprogramming produces iCMs that are transcriptionally more similar to adult 
cardiomyocytes than iCMs generated in the absence of inhibitors (Mohamed et al., 2016). Inhibition of 
TGF signaling reduces transcription of fibroblast and extracellular matrix associated genes, while 
inhibition of Wnt signaling affects chromatin accessibility (Mohamed et al., 2016). Together, the dual 
inhibition of TGF and Wnt signaling increases expression of mature cardiomyocyte markers including 
ion channels, calcium handling genes, and components of fatty acid metabolism (Mohamed et al., 2016). 
These studies demonstrate that residual fibroblast signature is a barrier to complete cell fate conversion 
and that repressing fibroblast gene expression enhances reprogramming in vitro.  
Mohamed et al. demonstrated that repression of residual fibroblast signature using TGF/Wnt 
inhibition also enhances reprogramming and cardiac function in vivo (Mohamed et al., 2016). In 
conjunction with TGF/Wnt inhibition, GMT transcription factor cocktail reprogramming increases 
ejection fraction, stroke volume, and cardiac output as early as one week post coronary artery ligation 
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(Mohamed et al., 2016). Histologic sections reveal that TGF/Wnt inhibition reduces scar size and 
produces thicker bands of fibroblast-derived reprogrammed iCMs re-muscularizing the infarct region 
(Mohamed et al., 2016). Lineage tracing indicates that TGF/Wnt inhibition during reprogramming 
produces a five-fold increase in iCM generation compared to reprogramming without inhibitors 
(Mohamed et al., 2016). TGF/Wnt inhibition also generates iCMs that are functionally more mature, 
with calcium and contraction kinetics more similar to adult cardiomyocytes (Mohamed et al., 2016).  
Intracellular Signaling Pathways 
Recent studies have examined the effect of intracellular signaling pathways on direct cardiac 
reprogramming. Zhou et al. modulated intracellular signaling pathways by screening a library of 192 
protein kinases to assess the effect on GHMT transcription factor reprogramming (Zhou et al., 2015). 
Akt1 activation increases reprogramming efficiency and produces iCMs with a more mature 
cardiomyocyte phenotype, exhibiting an increase in calcium flux, spontaneous beating, polynucleation, 
cellular hypertrophy, mitochondrial function, cardiac marker expression, and sarcomere assembly (Zhou 
et al., 2015). Akt1 does not enhance the expression of the GHMT reprogramming factors (Zhou et al., 
2015). Rather, Akt1 functions through its downstream targets, activating mTOR and inhibiting Foxo3a 
which have roles in the regulation of mitochondrial metabolism, myocyte development, and gene 
expression (Zhou et al., 2015). 
Abad et al. screened seven small molecule compounds with a demonstrated role in iPSC 
reprogramming and found that the Notch inhibitor DAPT enhances GHMT transcription factor cocktail 
reprogramming (Abad et al., 2017). Notch pathway signaling plays an important role in cardiac 
development by regulating cardiomyocyte differentiation and proliferation (Abad et al., 2017). Non-
canonical Notch signaling blocks the binding of transcription factor Mef2c to promoter regions (Abad et 
al., 2017). In the context of iCM reprogramming, Notch inhibition acts in coordination with Akt1 to 
increase the acquisition of a mature cardiomyocyte phenotype, demonstrated by increased calcium flux, 
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sarcomere assembly, and spontaneous beating (Abad et al., 2017). GHMT reprogramming with Akt1 
activation and Notch inhibition generated up to 70% conversion efficiency with 45% of the 
reprogrammed iCMs exhibiting spontaneously beating (Abad et al., 2017). Notch inhibition modulates 
transcriptional programs involved in cardiomyocyte differentiation and development by increasing the 
binding of transcription factor Mef2c to cardiac loci promoters (Abad et al., 2017). 
Mohamed et al. screened a library of 5,500 small molecule compounds in an unbiased, high 
throughput approach to determine cell signaling pathways that modulate reprogramming and identified 
the WNT and TGF signaling pathways as barriers to reprogramming (Mohamed et al., 2016). Inhibiting 
both pathways improves GMT transcription factor cocktail reprogramming in vitro and in vivo 
(Mohamed et al., 2016). TGF/Wnt inhibition enhances reprogramming efficiency and speed in vitro 
(Mohamed et al., 2016). GMT reprogramming with both inhibitors produces 30% MHC-GFP reporter 
expression, while only one inhibitor produces 15% and no inhibitors produces only 4% (Mohamed et al., 
2016). GMT reprogramming with both inhibitors generates beating iCMs within one week, while only 
one inhibitor requires three weeks and no inhibitors requires six to eight weeks (Mohamed et al., 2016). 
TGF/Wnt inhibition also enhances reprogramming and cardiac function in vivo (Mohamed et al., 2016) 
(See “Repression of Fibroblast Identity”). RNA sequencing reveals that iCMs reprogrammed in the 
presence of the TGF inhibitor downregulate fibrotic and extracellular matrix associated genes, while 
iCMs reprogrammed in the presence of the WNT inhibitor downregulate genes affecting chromatin 
modulation, nucleosome organization, and DNA packaging. 
Growth Factors 
Multiple studies have noted greater conversion efficiency or more complete functional 
maturation of iCMs reprogrammed in vivo over in vitro (Inagawa et al., 2012; Ma et al., 2015; Qian et al., 
2012; Song et al., 2012). In vivo reprogrammed iCMs are more similar to endogenous cardiomyocytes 
than in vitro reprogrammed iCMs. This suggests that unidentified extrinsic factors in the in vivo 
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microenvironment such as topographic cues, mechanical forces, growth factors, cytokines, or paracrine 
signaling play an important role in promoting iCM maturation. 
Lack of requisite growth factors constitutes a barrier to reprogramming. Yamakawa et al. noted 
that under serum-based culture conditions, in vitro reprogramming generated incompletely converted, 
immature iCMs (Yamakawa et al., 2015). Although many reporter positive cells were observed at early 
time points, few remained marker positive after four weeks of culture (Yamakawa et al., 2015). The 
authors screened eight cardiogenic compounds to create a serum-free cell culture media containing 
fibroblast growth factor (FGF) 2, FGF 10, and vascular endothelial growth factor (VEGF) that greatly 
enhances the in vitro generation of functionally mature iCMs that contract spontaneously and exhibit 
calcium oscillations (Yamakawa et al., 2015). The optimized media (FFV) increases the maturity of 
reprogrammed cells by activating cardiac transcriptional regulators, the p38 MAPK pathway, and the 
PI3K/AKT pathway (Yamakawa et al., 2015). Additionally, reprogramming with Mef2c and Tbx5 in FFV 
media upregulates endogenous Gata4 expression and removes the requirement for exogenous Gata4 
expression as a reprogramming factor (Yamakawa et al., 2015), similarly to our findings (Zhou et al., 
2016). The growth factors in FFV media are critical for late stage maturation but do not affect early 
reprogramming events (Yamakawa et al., 2015). Christoforou et al. also observed that iCMs cultured in 
high serum media fail to assemble -Actinin or cTnT positive sarcomeres (Christoforou et al., 2013). Use 
of low serum growth media increases the assembly of -Actinin/cTnT double positive sarcomeres 
(Christoforou et al., 2013). However, reprogrammed cells lose striated sarcomere staining over time. By 
day 30 most double positive cells do not exhibit organized sarcomeres (Christoforou et al., 2013). These 




In addition to growth factors, environmental cues are important in developing the functional 
maturity of iCMs. Cultured cardiomyocytes respond differently to the stiffness of the in vitro substrate 
(Chopra et al., 2012). Polyacrylamide gels with a stiffness between 10-30 kPa favor cardiomyocytes with 
a spread and elongated morphology that form well organized, polarized sarcomeres. However, stiff 
substrates produce cells with F-actin stress fibers that lack organized sarcomeres, while soft substrates 
produce cells with rounded morphology and disorganized sarcomeres. These findings suggest that the 
cardiomyocyte cytoskeleton remodels based on substrate stiffness (Chopra et al., 2012). However, GMT 
transcription factor cocktail reprogramming of adult tail tip fibroblasts on substrates of 1, 21, and 62 kPa 
does not have an effect on reprogramming efficiency even though variation in substrate stiffness 
successfully induces a range of morphologies (Sia et al., 2016). Culturing reprogramming cells under 
conditions of periodic uniaxial stretch also fails to increase reprogramming efficiency, although cells 
orient in response (Sia et al., 2016). 
While direct cardiac reprogramming is unaffected by in vitro substrate stiffness or mechanical 
stretch, reprogramming does respond to other topographical cues. Morez et al. demonstrated that the 
forward programming of cardiac progenitor cells using the cardiac lineage transcription factor cocktail 
Myocardin, Tbx5, and Mef2c is enhanced by topographical cues which modulate histone acetylation 
(Morez et al., 2015). Sca1+ adult progenitor cells were reprogrammed on flat or microgrooved collagen I 
coated polydimethylsiloxane substrates. Reprogramming efficiency and sarcomere assembly are 
enhanced on microgrooved substrates compared to flat substrates (Morez et al., 2015). Culture on 
microgrooved substrates increases histone 3 acetylation in differentiating cells (Morez et al., 2015). 
Treatment with the histone deacetylase inhibitor VPA produces a similar increase in reprogramming 
efficiency and increase in histone 3 acetylation in cells reprogrammed on a flat substrate (Morez et al., 
2015). VPA treatment does not produce an additive effect on the reprogramming efficiency of cells 
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cultured on microgrooved substrates, indicating that culture on microgrooved substrates increases 
histone acetylation (Morez et al., 2015). Culturing on microgrooved substrates also significantly 
enhances iCM sarcomere assembly compared to flat substrates (Morez et al., 2015). Unlike 
reprogramming efficiency, sarcomere organization is independent of histone 3 acetylation (Morez et al., 
2015). These results indicate that topographical cues improve cardiomyocyte reprogramming efficiency 
and maturation (Morez et al., 2015). Furthermore, Sia et al. demonstrated that GMT reprogrammed 
adult tail tip fibroblasts cultured on a microgrooved substrate show increased reprogramming and 
beating through a histone acetylation and transcriptional activation mechanism (Sia et al., 2016). Cells 
cultured in microgrooves align along the grooves and exhibit an elongated morphology (Sia et al., 2016). 
Reprogramming in microgrooves generates two-fold more cTnT positive, sarcomere positive, and 
beating iCMs than reprogramming on flat surfaces (Sia et al., 2016). Microgroove cultured iCMs have 
1.5-fold higher nuclear localization of the mechanosensitive transcription factor Mkl1 than iCMs 
cultured on flat surfaces (Sia et al., 2016). Blebbistatin treatment prevents Mkl1 nuclear localization and 
reduces the reprogramming yield of iCMs on microgrooved surfaces to that of flat surfaces (Sia et al., 
2016). Jasplakinolide and Cytochalasin D promote Mkl1 nuclear localization and increase the yield of 
iCMs cultured on flat surfaces to that of grooved surfaces (Sia et al., 2016). However, overexpressing 
Mkl1 during reprogramming on flat surfaces only partially accounts for the increase in reprogramming 
seen on grooved surfaces (Sia et al., 2016). Consistent with the findings of Morez et al., Sia et al. show 
that culturing on microgrooves increases histone 3 acetylation (Sia et al., 2016). Simultaneous HDAC 
inhibition using VPA and Mkl1 overexpression completely account for the increase in reprogramming on 
grooved surfaces (Sia et al., 2016). 
The identity and composition of the extracellular matrix also impacts cardiomyocyte phenotype 
and reprogramming. Substrate adhesive ligands alter cardiomyocyte sarcomere organization and 
maturation through integrin signaling. Sarcomeres are well organized and polarized when 
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cardiomyocytes are cultured on fibronectin coated polyacrylamide substrates but not on collagen I 
coated polyacrylamide (Chopra et al., 2012). Culturing cardiomyocytes on hyaluronic acid instead of 
polyacrylamide gels partially removes cardiomyocyte dependence on substrate stiffness and allows cells 
to organize mature sarcomeres on softer substrates (Chopra et al., 2012). These findings suggest that 
the cardiomyocyte cytoskeleton remodels based on adhesive ligand signaling (Chopra et al., 2012). 
Consequently, extracellular matrix composition also influences cardiac reprogramming (Kong et al., 
2013). Using an indirect reprogramming method that employs de-differentiation followed by directed 
cardiac differentiation, Kong et al. compared reprograming efficiency on hydrogels incorporating 
Matrigel, collagen I, or fibrin extracellular matrix proteins (Kong et al., 2013). Reprogramming on fibrin 
gels yields the greatest number of contractile cardiomyocyte colonies, and supplementation with 
ascorbic acid, which promotes cellular collagen synthesis, increases contractile colony size (Kong et al., 
2013). Contractile colonies stain positive for collagen while non-contractile colonies are negative (Kong 
et al., 2013). Furthermore, the addition of collagen I to fibrin hydrogels promotes cardiac differentiation 
and increases the generation of contractile colonies (Kong et al., 2013). These findings demonstrate that 
the composition of extracellular matrix proteins for in vitro cell culture substrates directly alters 
reprogramming efficiency and maturity. 
To more accurately mimic environmental stimuli in vivo, Li et al. cultured reprogramming iCMs 
in a 3D fibrin hydrogel and demonstrated that 3D culture enhances direct cardiac reprogramming (Li et 
al., 2016).  Compared with 2D culture, 3D hydrogel culture increases cardiac gene expression and cTnT 
and -Actinin immunostaining in both microRNA reprogramming cocktail and control microRNA 
conditions (Li et al., 2016). While microRNA cocktail reprogramming on traditional 2D tissue culture 
plates produces a five-fold increase in MHC-CFP reporter expression, reprogramming in 3D fibrin 
hydrogels generates a twenty-fold increase in reporter expression (Li et al., 2016). Fibrin hydrogel 3D 
culture also increases matrix metalloproteinase (MMP) expression (Li et al., 2016). Broad spectrum 
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pharmacological inhibition of MMP activity abolishes the increase in reprogramming from fibrin 
hydrogel 3D culture, indicating that 3D culture enhances reprogramming through a MMP-mediated 
mechanism (Li et al., 2016). The role of MMPs in enhancing direct cardiac reprogramming in 3D culture 
suggests that the upregulation of MMPs in infarcted hearts could be a contributing factor to the greater 
reprogramming efficiency in vivo compared to in vitro (Li et al., 2016).  
Manipulation of in vivo conditions also has the potential to improve reprogramming. Promoting 
angiogenesis through preconditioning with VEGF increases in vivo reprogramming efficiency and 
improves therapeutic restoration of cardiac function (Mathison et al., 2012). Pro-angiogenic VEGF 
treatment increases the vascularization of the infarct zone in rat hearts following myocardial infarction 
(Mathison et al., 2012). VEGF preconditioning also increases the number of Myh7 positive 
cardiomyocytes in the infarct zone of GMT treated hearts and increases ejection fraction by four-fold 
(Mathison et al., 2012). Promoting fibroblast activation and migration through thymosin b4 treatment 
also enhances in vivo reprogramming efficiency (Qian et al., 2012). Thymosin b4 injection increases 
fibroblast proliferation in mouse hearts following myocardial infarction (Qian et al., 2012). Thymosin b4 
treatment in conjunction with GMT reprogramming increases the generation of iCMs, improves cardiac 
function, and reduces scar size (Qian et al., 2012). 
Future Direction 
Additional research is required to translate direct cardiac reprogramming into a clinical therapy. 
Necessary steps include continued basic research, research in large animal models, improvement in 
human reprogramming, and bioengineering of delivery mechanisms. 
A better understanding is needed of the mechanism of late stage reprogramming events and 
iCM maturation. Research in this area is currently hindered by inefficiency in the reprogramming 
process. Asynchronous, heterogeneous cell populations produce low rates of fully reprogrammed cells 
making it difficult to acquire sufficient cell numbers to study late stage reprogramming events. Early 
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stage studies are aided by the comparative synchrony of cells early in the reprogramming process that 
provides a large sample population. 
Research in large animal models is also required to move direct cardiac reprogramming toward 
clinical application. The efficiency of housing, breeding, and handling rodents has made them the most 
widely used animal models in biomedical research. Additionally, a wealth of tools has been developed 
specifically for murine research, including imaging techniques, in vivo monitoring systems, and genetic 
manipulation, making the mouse a particularly productive model. However, the mouse exhibits 
significant cardiovascular differences compared to humans. In addition to obvious differences such as 
small size and short lifespan, mice differ from humans in a range of anatomical, physiological, energetic, 
electrophysical, and mechanical properties that include heart rate, coronary artery structure, and 
contraction/relaxation kinetics. Large animal models such as the dog, sheep, or pig have greater 
physiologic resemblance to humans with similar body size, heart size, and heart rate. In fact, 
physiological similarities between pigs and humans are close enough to make the pig an ideal 
xenotransplant donor. Recent progress in genetic manipulation of pigs will contribute to the use of the 
pig as a cardiovascular disease model. 
Although significant progress has been achieved in uncovering the molecular barriers to direct 
reprogramming in mice, research in reprogramming human cells lags far behind. Reprogramming human 
fibroblasts requires the addition of extra factors but yields far lower conversion efficiency. 
Spontaneously beating cells are rare, indicating that more work is required to translate findings from the 
mouse to human and uncover undiscovered molecular barriers in human reprogramming. 
Finally, a safe and efficient delivery system is required for the translation of direct cardiac 
reprogramming to clinical use. Current in vivo research uses direct injection of retroviral vectors into the 
infarct zone. While conceivably, direct cardiac injection could be achieved in some myocardial infarct 
patients during coronary bypass surgery, a non-invasive delivery method is preferable. Additionally, 
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retroviral vectors integrate into the host cell genome, incurring the risk of gene disruption and cellular 
transformation. The ideal delivery vector would be non-integrating with a high transfection efficiency, 
specificity for the target cell type, and adequate capacity to accommodate multiple reprogramming 
factors. Adenoviruses are promising viral vectors for the delivery of reprogramming factors. The most 
commonly employed vector in clinical trials, adenoviruses are non-integrating, have large capacity and a 
high transduction efficiency. Additionally, recent research using small molecules to achieve 
reprogramming and developments in nanoparticle delivery systems offer potential alternatives to viral 
vector reprogramming factor delivery. 
Addendum 
Since publication of this review paper in 2017, significant discoveries have advanced our 
understanding the molecular mechanisms and regulation of direct cardiac reprogramming. Using broad, 
unbiased approaches such as transcriptomics, proteomics, and epigenomics, several key studies have 
delineated the sequence of molecular events that occur during direct cardiac reprogramming, 
reconstructing the trajectory and decision points of cell fate conversion. Findings from these studies 
have uncovered pathways and networks involved in the induction and regulation of direct cardiac 
reprogramming.  
First, Liu et al. used single cell transcriptomics to reconstruct the cell fate trajectory of 
fibroblasts in the process of reprogramming into cardiomyocytes (Liu et al., 2017a). The study identified 
molecularly distinct subpopulations of reprogramming iCMs and described an inverse relationship 
between cellular proliferation and reprogramming induction. Additionally, the transcriptomics data 
identified a downregulation of RNA processing and splicing factors during reprogramming. Building on 
these findings, Zhou et al. performed a loss-of-function screen of RNA splicing factors to identify factors 
that are either barriers or enhancers of reprogramming (Zhou et al., 2018). This study continued and 
expanded their previous loss-of-function screen of epigenetic factors during reprogramming (Zhou et al., 
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2016) by also including epigenetic factors involved in chromatin remodeling and identified several 
additional epigenetic and splicing factors that are either inhibitory to or necessary for reprogramming.  
Using proteomics, Sauls et al. demonstrated that the initiating events of direct cardiac 
programming follow a series of ordered, temporal steps (Sauls et al., 2018). Sauls et al. performed 
quantitative mass spectroscopy and identified temporal changes in protein abundance during early 
stage reprogramming (Sauls et al., 2018). These changes involve specific functional classes of proteins 
including extracellular matrix proteins, translation factors, and chromatin binding proteins. The study 
constructed protein relational networks that reveal pathways involved in the induction of iCM 
reprogramming.  
Subsequently, in an epigenetics approach, Hashimoto et al. used genome-wide ChIP sequencing 
to show that cell fate conversion is initiated by the coordinated activity of reprogramming transcription 
factors binding at cardiac enhancers and activating a cardiogenic gene regulatory network (Hashimoto et 
al., 2019). Hashimoto et al. demonstrate that the transcription factors Gata4, Hand2, Mef2c, and Tbx5 
are simultaneously recruited to cardiac loci during reprogramming and that transcriptional activity 
primarily occurs near Mef2c binding sites. Hand2 and Akt1 facilitate transcription factor access to 
Mef2c-enriched enhancer elements and thus increase transcription factor co-occupancy at cardiac loci 
(Hashimoto et al., 2019). Similarly, Abad et al. show that inhibiting Notch enhances direct cardiac 
reprogramming by increasing Mef2c transcriptional activity (Abad et al., 2017). The classical Notch 
inhibitor, DAPT, cooperates with Akt1 to increase Mef2c binding at cardiac loci promoters, increasing 
the reprogramming efficiency and maturation of iCMs (Abad et al., 2017). Furthermore, Wang et al. 
demonstrate that the isoform of Mef2c used as a reprogramming factor affects reprogramming (Wang 
et al., 2020).  Wang et al. show that the Mef2c isoform Mi2 induces higher reprogramming efficiency 
than Mi4 (Wang et al., 2020). These studies further highlight the particular importance of Mef2c in 
reprogramming first demonstrated experimentally by Wang et al. (Wang et al., 2015a). 
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Two studies performed large screens to identify factors that will enhance the reprogramming of 
refractory adult fibroblasts. Zhou et al. performed a screen of transcription factors and cytokines to 
identify candidates that would enhance reprogramming of adult mouse fibroblasts (Zhou et al., 2017a). 
Zhou and colleagues found that zinc finger transcription factor 281 (ZNF281) enhances adult fibroblast 
reprogramming through association with Gata4 at cardiac enhancers (Zhou et al., 2017a). Similarly, 
Muraoka et al. screened chemical compounds and found that the non-steroidal anti-inflammatory drug, 
diclofenac sodium (diclofenac), enhanced reprogramming of adult murine fibroblasts by inhibiting 
cyclooxygenase-2-mediated prostaglandin E2-prostaglandin E receptor 4 signaling, thereby silencing 
fibroblast and inflammatory programs (Muraoka et al., 2019). 
In addition to these studies employing unbiased experimental approaches, other studies have 
interrogated specific pathways using hypothesis-driven approaches. While Liu et al. described an inverse 
relationship between successful fibroblast reprogramming and cellular proliferation rates in their 
transcriptomics data (Liu et al., 2017a), Bektik et al. used a hypothesis-driven approach to explore the 
role of the cell cycle in reprogramming. Bektik et al. used time-lapse imaging to show that 
reprogramming is primarily initiated at the late G1 or S phase of the cell cycle and that many 
reprogramming cells divide shortly after reprogramming induction (Bektik et al., 2018). However, Bektik 
et al. show that successfully reprogrammed cells exit the cell cycle during the reprogramming process 
and that enhancing cell cycle exit improves reprogramming rates (Bektik et al., 2018). In another 
hypothesis-driven approach, Mathison et al. were intrigued by observations that in vivo reprogramming 
reduces ventricular fibrosis in an effect apparently disproportionate to the number of new 
cardiomyocytes generated (Mathison et al., 2017). Mathison and colleagues demonstrated that 
reprogramming factor Gata4 activates antifibrotic regulatory pathways through direct repression of the 
profibrotic mediator Snail and downregulation of the profibrotic factors connective tissue growth factor, 
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collagen1a1, and fibronectin to reduce fibrosis in hearts following direct cardiac reprogramming 
(Mathison et al., 2017).  
In addition to these studies in mouse, significant advances have been made in reprogramming 
human fibroblasts. Bektik et al. screened additional factors to improve the reprogramming of human 
fibroblasts and found that the addition of Hand2 and microRNA miR-1 to their 7 factor reprogramming 
cocktail enhanced reprogramming (Bektik et al., 2017). Zhou et al. performed single cell transcriptomics 
to analyze the reprogramming trajectory of human fibroblasts reprogrammed with a 4 factor 
reprogramming cocktail consisting of polycistronic human Mef2c-Gata4-Tbx5 and microRNA miR-133 
(Zhou et al., 2019). Zhou and colleagues found that reprogramming fibroblasts reached a decision point 
where their trajectory bifurcated, with some regressing back to a fibroblast fate and others continuing 
on to acquire a cardiomyocyte fate (Zhou et al., 2019). The authors also developed a cell fate index to 
qualitatively assess the degree of reprogramming progress that can be used in other cell fate transitions. 
Finally, advances have been made in improving delivery mechanisms using nanoparticles (Chang 
et al., 2019) and Sendai virus vectors (Miyamoto et al., 2018). 
Present Work 
Before direct cardiac reprogramming is ready to be used as a clinical therapy, additional 
research is required to improve the efficiency of the reprogramming process and the purity and maturity 
of the generated iCMs. Naturally, to improve the process, we must first have a detailed understanding of 
how it works. This was the motivation for my dissertation research. My studies seek to shed new light on 
epigenetic regulation of reprogramming induction and molecular mechanisms of iCM maturation. I first 
developed a series of cell lines as tools for ongoing research (Chapter 2). These cell lines have enabled 
studies performing large-scale screens of potential regulatory factors, including the loss-of-function 
screen of RNA splicing factors referenced above (Liu et al., 2017a). I next explored the epigenetic 
regulation of early-stage reprogramming events to increase the efficiency of the reprogramming process 
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(Chapter 3). Finally, I described a novel mitochondrial mechanism regulating iCM reprogramming 







CHAPTER 2: GENERATION OF AN INDUCIBLE FIBROBLAST CELL LINE FOR STUDYING DIRECT 
CARDIAC REPROGRAMMING2 
Introduction 
Direct cardiac reprogramming of fibroblasts into cardiomyocyte-like cells offers additional 
strategies for cardiac regeneration and disease modeling. The expression of three cardiac-lineage 
transcription factors – Mef2c, Gata4, and Tbx5 (MGT) – is sufficient to convert fibroblasts directly into 
induced cardiomyocytes (iCMs) in vitro (Ieda et al., 2010) and in vivo (Qian et al., 2012). A polycistronic 
construct with the three transcription factors separated by peptide cleavage sites yields 
stoichiometrically optimal ratios of the three reprogramming factors (Wang et al., 2015a). This 
polycistronic MGT construct produces improved reprogramming efficiency in vitro (Wang et al., 2015a) 
and improved reprogramming efficiency and cardiac function in vivo (Ma et al., 2015). To facilitate 
studies in direct cardiac reprogramming, we developed a suite of tools for iCM research including a 
transformed fibroblast cell line with a cardiac reporter, an inducible polycistronic reprogramming 
construct, and an inducible reprogrammable fibroblast cell line. 
Materials and Methods 
All cell lines and constructs described here will be made available to the research community. 
Primary Cell Culture and Immortalization. 
Mouse embryonic fibroblasts (MEF) were isolated as previously described (Jozefczuk et al., 
2012) from αMHC-GFP reporter mice (Ieda et al., 2010; Qian et al., 2012). Animal care was performed in 
 
2 Chapter 2 was published as a research article in Genesis. Its formal citation is: Vaseghi, H.R., Yin, C., Zhou, Y., 
Wang, L., Liu, J., and Qian, L. (2016). Generation of an inducible fibroblast cell line for studying direct cardiac 
reprogramming. Genes. N. Y. N 2000 54, 398–406. 
28 
accordance with the guidelines established by University of North Carolina, Chapel Hill. MEF were 
seeded at a density of 5x104 cells per well in a 6 well plate coated with 0.01% gelatin. The following day, 
cells were lentivirally infected with large T-antigen with Zeocin resistance (AddGene #1779). Two days 
later, cells were re-plated in media with 300 g/mL Zeocin. Antibiotic selection was maintained until all 
uninfected cells in control wells had died. 
Propidium Iodide Cell Cycle Analysis. 
MEF and MEF-T were seeded at a density of 4x104 cells per well in 24 well plates coated with 
0.01% gelatin. After 48 hours of culture, cells were dissociated with 0.025% Trypsin-EDTA, washed once 
with 2% FBS in PBS and once with PBS, and fixed in 70% ethanol overnight at -20°C. Fixed cells were 
pelleted, washed twice in 1% BSA in PBS, resuspended in PBS with 10 g/mL RNaseA and 50 g/mL PI, 
and analyzed immediately by flow cytometry. Data was collected on an Accuri C6 cytometer 
(BetaDickson) and analyzed using FlowJo software (Tree Star). 
Ki67 Nuclear Antibody Staining. 
MEF and MEF-T were seeded at a density of 4x104 cells per well in 24 well plates coated with 
0.01% gelatin. After 48 hours of culture, cells were dissociated with 0.025% Trypsin-EDTA, washed once 
with 2% FBS in PBS and once with PBS, and fixed in 70% ethanol overnight at -20°C. Fixed cells were 
pelleted, washed in 1% BSA/PBS, resuspended in 50 L rabbit anti-Ki67 antibody (1:500, Abcam) in 1% 
BSA/PBS for 30 minutes at room temperature, washed twice in 1% BSA/PBS, resuspended in 50 L Alexa 
Fluor 488–conjugated donkey anti-rabbit IgG (1:500, Jackson ImmunoResearch, Inc.) in 1%BSA/PBS for 
30 minutes at 4°C, washed twice in 1% BSA/PBS, resuspended in PBS, and analyzed by flow cytometry. 
Data was collected on an Accuri C6 cytometer (BetaDickson) and analyzed using FlowJo software (Tree 
Star). 
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EdU Incorporation and Staining. 
MEF and MEF-T were seeded at a density of 4x104 cells per well in 24 well plates coated with 
0.01% gelatin. After 48 hours of culture, EdU was added to the cell culture media to a final 
concentration of 10 M and incubated for 2.5 hours. For flow cytometry analysis, cells were harvested 
and EdU incorporation was visualized using a Click-iT Plus EdU Flow Cytometry Assay Kit (Life 
Technologies, C10632) according to the manufacturer’s instructions. Cells were counted on an Accuri C6 
cytometer (BetaDickson) and analyzed using FlowJo software (Tree Star). For immunocytochemistry, 
cultures were washed with 3% BSA in PBS three times and fixed with 4% paraformaldehyde (EMS) at 
room temperature (RT) for 15 min. After permeabilization with 0.2% Triton in PBS for 20 min at RT, EdU 
incorporation was visualized with 500 L of Click-iT Plus reaction cocktail (Life Technologies, C10632) 
according to the manufacturer’s protocol incubated for 30 minutes. After washing with PBS three times, 
nuclei were stained with Hoechst 33342 (Life Technologies). Images were acquired using EVOS® FL Auto 
Cell Imaging System (Life Technologies). 
Viral Transduction and Efficiency Determination. 
MEF and MEF-T were seeded at a density of 2x104 cells per well in 24 well plates coated with 
0.01% gelatin and infected with virus the following day in iCM media (4:1 DMEM:M199 with 10% FBS) 
with 4 g/mL polybrene. Three days post infection, cells were dissociated with 0.025% Trypsin-EDTA, 
washed and resuspended in PBS. Transduction efficiency was analyzed immediately by flow cytometry. 
Data was collected on an Accuri C6 cytometer (BetaDickson) and analyzed using FlowJo software (Tree 
Star). 
Characterization of iMEF by Flow Cytometry. 
iMEF were seeded at a density of 2x104 cells per well in 24 well plates coated with 0.01% gelatin 
and infected with virus the following day in iCM media (4:1 DMEM:M199 with 10% FBS) with 4 g/mL 
polybrene and 1 g/mL doxycycline. Three days post infection, cells were dissociated with 0.025% 
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Trypsin-EDTA, washed and resuspended in PBS. Transduction efficiency was analyzed immediately by 
flow cytometry. Data was collected on an Accuri C6 cytometer (BetaDickson) and analyzed using FlowJo 
software (Tree Star).  
Inducible Polycistronic Reprogramming Construct (iMGT) Cloning 
A modified pTRIPZ (Thermo Scientific, now Dharmacon) vector described previously (Zheng et 
al., 2014) was a kind gift from Qing Zhang. Our polycistronic MGT construct (Wang et al., 2015b) was 
cloned into the vector behind the tet operator sites and minimal CMV promoter using the AgeI and ClaI 
restriction enzyme sites. WPRE was amplified from the vector with primers to include flanking KpnI and 
MluI cleavage sites. Digestion of the vector with the enzymes MluI and KpnI removed a segment from 
base pairs 4064 to 8019 that included WPRE, rtTA3, PuroR, and the shRNAmir insertion site. This 
removal of the second KpnI site at bp 6543 leaves a single KpnI site at bp 8019. The WPRE PCR amplicon 
was digested with KpnI and MluI and ligated into the vector. The resulting construct contains 
polycistronic MGT in frame behind the tet operator sites and minimal CMV promoter and lacks rtTA3 
and PuroR. For the co-expression of rtTA with the iMGT construct, a pTRIPZ vector was digested with the 
enzymes XbaI and MluI and re-ligated to remove the tet operator sequences and minimal CMV 
promoter. In this construct, rtTA3 is constitutively expressed under the human ubiquitin C promoter. 
The transcriptional activator rtTA3 is sensitive to doxycycline dosage and can be titrated to regulate 
transcriptional activity  (Das et al., 2004). 
Cardiac Reprogramming Using the icMEF Cell Line. 
icMEF were seeded at a density of 2x104 cells per well in 24 well plates coated with 0.01% 
gelatin. The following day, media was changed to iCM media (4:1 DMEM:M199 with 10% FBS) with 1 
g/mL doxycycline. Three days post infection, cells were dissociated with 0.025% Trypsin-EDTA, washed 
and resuspended in PBS. Transduction efficiency was analyzed immediately by flow cytometry. Data was 
collected on an Accuri C6 cytometer (BetaDickson) and analyzed using FlowJo software (Tree Star). 
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Growth Curve. 
MEF-T were seeded at a density of 1x105 cells per well in 6 well plates coated with 0.01% 
gelatin. Wells were harvested in triplicate and cells counted by hemocytometer at 24-hour intervals for 
eight days. 
Immunocytochemistry. 
Cells were washed with PBS three times and fixed with 4% paraformaldehyde (EMS) at room 
temperature (RT) for 15 min. After permeabilization with 0.2% Triton/PBS for 15 min and blocking in 5% 
BSA for 1 hour, cells were treated with primary antibody at 4°C overnight, secondary antibody for 1 hour 
at RT, and nuclei staining with Hoechst 33342 (Life Technologies). The following antibodies were used: 
Rabbit anti-Ki67 (1:500, Abcam), rabbit anti-GFP (1:500, Life Technologies), Alexa Fluor 488–conjugated 
donkey anti-rabbit IgG (1:500, Jackson ImmunoResearch, Inc.). RFP reporter fluorescence was imaged 
without antibody staining. Images were acquired using EVOS® FL Auto Cell Imaging System (Life 
Technologies). 
Western Blotting. 
Cells were lysed in 2x SDS loading buffer (Bio-Rad). Proteins in cell lysate was separated by SDS-
PAGE, transferred to nitrocellulose membranes, and probed with the following antibodies: Mef2c 
(1:1000, Abcam), Gata4 (1:200, Santa Cruz Biotechnology), Tbx5 (1:200, Santa Cruz Biotechnology), or β-
Actin (1:1000, Santa Cruz Biotechnology). The target proteins were detected by chemiluminescence 
(ECL, Thermo Fisher Scientific). The membranes were stripped with stripping buffer (Sigma) and re-
probed with antibody against a second protein or β-Actin as a loading control. 
Real Time Quantitative Polymerase Chain Reaction. 
Total RNA was harvested from icMEF cultures three days after doxycycline addition by standard 
phenol/chloroform isolation using TRIzol reagent (Thermo Fisher Scientific). cDNA was obtained by 
SuperScript III Reverse Transcriptase (Thermo Fisher Scientific) according to the manufacturer’s 
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protocol. RT-qPCR was performed on a ViiA 7 Real-Time PCR System (Applied Biosystems) with SYBR 
Green (Thermo Fisher Scientific) or TaqMan (Thermo Fisher Scientific) chemistry. 
Statistical Analyses. 
The statistical significance of differences between groups was analyzed using a two-way 
unpaired student’s t-test. A p-value < 0.05 was regarded as significant. Error bars indicate standard 
deviation. 
Results 
Development of the mouse embryonic fibroblast cardiac reporter cell line MEF-T. 
First, we developed a cardiac reporter fibroblast cell line. We isolated mouse embryonic 
fibroblasts (MEF) at embryonic day 13.5 from  myosin heavy chain-green fluorescent protein (MHC-
GFP) cardiac reporter strain mice (Ieda et al., 2010; Qian et al., 2012) (Figure 2.1A). This transgenic strain 
drives GFP reporter expression with the cardiac MHC promoter. Cardiomyocytes from MHC-GFP mice 
are GFP positive, while fibroblasts are GFP negative. Consequently, primary MEFs isolated from MHC-
GFP embryos are GFP negative; however, MEFs that have been reprogrammed into iCMs through the 
forced expression of cardiac lineage specific transcription factor cocktails are GFP positive. We 
transformed primary MHC-GFP MEFs with retroviral delivery of SV40 large T antigen (Hahn et al., 2002) 
and selected transformed cells with Zeocin (Figure 2.1A). The transformed mouse embryonic fibroblast 
cell line, MEF-T, is morphologically similar to parental primary MEF (Figure 2.1B). However, MEF-Ts are 
more prolific than primary MEFs and have a shorter population doubling time (Figure 2.1C). Accordingly, 
a higher proportion of MEF-Ts are active in the cell cycle compared to primary MEFs (Figure 2.1D). 
Propidium iodide staining and DNA content analysis reveal that 31% of MEF-Ts are in S phase compared 
to only 9% of primary MEFs (Figure 2.1D). Additionally, nucleotide analog EdU incorporation confirms 
that more MEF-Ts are actively synthesizing DNA than MEFs (Figure 2.1E). A 2.5-hour EdU pulse labeled 
49% of MEF-T cells compared to 19% of primary MEFs. The proportion of MEF-T cells positive for the 
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proliferation marker Ki67 is also over 2-fold higher than primary MEFs (Figure 2.1F). These data 
demonstrate that MEF-T is a transformed, highly proliferative fibroblast cell line.   
We next determined the potential of the MEF-T cell line for transgene expression using three 
common laboratory techniques: a lipid-based transfection reagent (Lipofectamine3000), lentiviral 
transduction, and retroviral transduction. First, we used Lipofectamine3000 to transfect primary MEF 
and MEF-T. Following transfection with a GFP-expressing plasmid, 35% of MEF-T expressed the GFP 
transgene compared to 7% of primary MEF (Figure 2.2A), indicating that MEF-T is significantly more 
susceptible to transfection using lipid-based transfection reagents than primary MEF. Second, we used a 
lentiviral vector to transduce primary MEF and MEF-T. A GFP-expressing lentivirus transduced 97% of 
MEF-T but only 57% of primary MEF (Figure 2.2B), indicating that MEF-T is also significantly more 
susceptible to transduction by lentiviral vectors. Third, to test a large construct encoded in a retroviral 
construct, we took advantage of our polycistronic system. We designed a retroviral construct to serve as 
a control for our polycistronic reprogramming construct Mef2c-Gata4-Tbx5 (MGT) (Wang et al., 2015a) 
by replacing the transcription factor Mef2c with the fluorescent reporter GFP to create the polycistronic 
construct GFP-Gata4-Tbx5 (GGT). GGT transduced 94% of MEF-T but only 61% of primary MEF (Figure 
2.2C). MEF-T is significantly more susceptible to retroviral transduction, lentiviral transduction, and 
Lipofectamine transfection. Finally, we assessed the duration of transgene expression of constructs of 
different sizes in the MEF-T cell line. The small GFP lentivirus produced sustained transgene expression, 
while the large GGT retrovirus produced a transient transgene expression (Figure 2.2D and 2.2E). The 
cardiac reporter fibroblast cell line MEF-T is the first reported of its kind and will be a valuable tool for in 
vitro studies involving activation of cardiac markers such as MHC. 
Development of the tetracycline-inducible gene expression MEF-T cell line iMEF. 
As an additional tool to facilitate studies in direct cardiac reprogramming, we incorporated the 
Tet-On inducible gene expression system (Das et al., 2004; Gossen et al., 1995; Zhu et al., 2002) into our 
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MEF-T cell line to permit the temporal regulation of factor expression during the reprogramming 
process. With constitutive expression of the engineered reverse tetracycline-controlled transcriptional 
activator (rtTA), transcription of genes under the control of the tetracycline responsive element tetO in 
the promoter can be regulated by the addition or removal of the tetracycline derivative doxycycline. In 
the absence of doxycycline, rtTA does not bind to the tetracycline responsive element in the promoter 
and fails to initiate transcription of the target genes. However, in the presence of doxycycline, rtTA binds 
to the promoter and initiates transcription of the target genes. We generated a MEF-T cell line that 
constitutively expresses rtTA for the temporal regulation of transgene expression, called inducible MEF 
(iMEF). We tested the TetOn system in iMEF using lentiviral infection with a tetracycline responsive RFP 
reporter construct (Figure 2.3A). iMEFs transduced with RFP do not express RFP in the absence of 
doxycycline; however, with the addition of doxycycline to the culture media, 87% of iMEFs robustly 
express the RFP reporter (Figure 2.3B). The spectral peak of uninfected iMEF overlaps completely with 
RFP infected iMEFs in the absence of doxycycline, indicating that the TetOn system is not leaky (Figure 
2.3B and 2.3C). The iMEF cell line is a valuable tool for temporal regulation of gene expression during 
reprogramming. One application of the iMEF cell line is to control RNA interference during 
reprogramming. Tetracycline-responsive short hairpin RNA can be used in combination with standard 
retroviral MGT to test the role of a gene of interest by knocking it down at specific times during the 
reprogramming process. Additionally, the initiation and duration of reprogramming factor expression 
can be controlled in iMEF if tetracycline-responsive promoters are used to drive transcription factor 
transcription. This system can be applied to the standard MGT cocktail or direct cardiac reprogramming 
cocktails utilizing additional factors such as Hand2, Myocardin, SRF, Nkx2.5, or miR-133 (Addis et al., 
2013; Christoforou et al., 2013; Jayawardena et al., 2012; Muraoka et al., 2014; Protze et al., 2012; Song 
et al., 2012). Furthermore, the iMEF cell line has broad applicability in direct lineage reprogramming 
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over and above direct cardiac reprogramming, as it can be employed to regulate the temporal 
expression of reprogramming cocktails for other lineages such as hepatocyte or neuron. 
Development of the tetracycline-inducible polycistronic MGT reprogramming factor construct iMGT. 
To complement the iMEF cell line, we designed a tetracycline-responsive MGT reprogramming 
factor construct for use in the Tet-On inducible gene expression system. We put the polycistronic MGT 
construct (Ma et al., 2015; Wang et al., 2015a) under the control of a tetracycline responsive promoter 
for temporal control of MGT reprogramming factor expression, creating an inducible polycistronic MGT 
construct (iMGT) (Figure 2.3D). In the absence of doxycycline, the reprogramming factors are not 
expressed; however, with the addition of doxycycline, stoichiometrically optimal ratios of the three 
transcription factors are expressed for optimal reprogramming efficiency (Figure 2.3D). When iMGT is 
co-expressed with rtTA in HEK 293T cells by either transfection or lentiviral delivery and doxycycline is 
supplied, the reprogramming factor protein expression is similar to that from the retrovirally expressed 
polycistronic MGT construct (Figure 2.3E). In the absence of doxycycline, the three reprogramming 
factors are not detected. 
Development of the tetracycline-inducible direct cardiac reprogramming cell line icMEF. 
Finally, we incorporated the iMGT construct into the iMEF cell line to generate a new cell line 
(icMEF) that can be reprogrammed simply by the addition of doxycycline to the culture media. The 
MHC-GFP cardiac reporter in the icMEF cell line indicates reprogramming with GFP reporter 
expression. Within three days of doxycycline addition, 23% of icMEF cells are GFP positive (Figure 2.3F 
and 2.3G). With doxycycline addition, icMEF also upregulate expression of cardiac genes, including 
sarcomere components Actc1 and Tnnt2 and ion channel subunits Slc8a1, Kcna5, and Scn5a (Figure 
2.3H). Similarly, inducible MGT expression in primary MEFs turns on αMHC-GFP reporter expression and 
cardiac marker cTnT expression detected by immunocytochemistry (Figure 2.3I). It is possible that the 
icMEFs that remain cardiac marker negative after doxycycline addition have undergone 
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transdifferentiation to some extent but have not yet turned on these markers. Such phenomenon is 
inherent in cell fate reprogramming due to the existence of a series of molecular barriers and the 
asynchronous conversion among starting cells that are not completely identical at the molecular and 
epigenetic levels. Single cell genomics will be the ultimate approach to determine how cell 






Figure 2.1. Characterization of the MEF-T cell line. A) Schematic of cell line development. Embryos are 
harvested from a pregnant female αMHC-eGFP mouse at embryonic day 13.5. Mouse embryonic 
fibroblasts (MEF) are isolated and transformed with lentiviral delivery of SV40 T antigen. Transformed 
cells are selected with Zeocin. B) Morphology of primary MEF and MEF-T cell line. Scale bar is 200 μm. C) 
Growth curve for MEF and MEF-T. D) Propidium iodide staining and DNA content analysis. E) 
Incorporation of nucleotide analog 5-ethynyl-2’-deoxyuridine (EdU). Scale bar is 200 μm. P < 0.0001. F) 




Figure 2.2. Transgene expression in the MEF-T cell line. A) Transfection with GFP transgene using 
Lipofectamine3000. Scale bar is 200 μm. P < 0.0001.  B) Lentiviral transduction with GFP transgene. Scale 
bar is 200 μm. P < 0.0001. C) Retroviral transduction with GFP-Gata4-Tbx5 (GGT) transgene. Scale bar is 




Figure 2.3. Inducible reprogramming constructs and cell lines. A) Schematic of the TetOn inducible 
gene expression system. B) Validation of the iMEF cell line using a tetracycline responsive RFP reporter 
lentiviral infection. P < 0.0001. C) Immunocytochemistry of controlled RFP reporter expression in iMEF. 
Scale bar is 200 μm. D) Schematic of the inducible polycistronic MGT (iMGT) construct. E) Western blot 
of reprogramming factor expression from the polycistronic and iMGT constructs. F) icMEF cell line 
reprogramming efficiency at three days after doxycycline addition. P < 0.0001. G) Immunocytochemistry 
of icMEF αMHC-eGFP reporter at three days after reprogramming with doxycycline. Scale bar is 200 μm.  
H) Real time quantitative PCR of cardiac sarcomere protein and ion channel subunit upregulation in 
icMEF three days after doxycycline addition. **** P < 0.0001. *** P = 0.0003  I) Immunocytochemistry 
of αMHC-eGFP reporter and cardiac Troponin T expression in primary MEF reprogrammed with iMGT 
and doxycycline. Scale bar is 20 μm.   
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Discussion 
In iPSC reprogramming, increased cellular proliferation through the inhibition of cell cycle 
regulation improves reprogramming efficiency (Hong et al., 2009; Kawamura et al., 2009; Li et al., 2009; 
Marión et al., 2009; Utikal et al., 2009; Zhao et al., 2008). In a similar manner, it is possible that SV40 T 
antigen-mediated transformation and increased proliferation of the icMEF cell line contributes to these 
relative higher rates of reporter expression and reprogramming efficiency when compared to the 
primary CF reprogramming. While we recently demonstrated that deletion of p53, p19, and p16 did not 
result in a significant increase in the percentage of generated iCMs (Zhou et al., 2016), the use of 
retroviruses to introduce the reprogramming factors inevitably links proliferation rate to reprogramming 
efficiency. Future experiments using quiescent fibroblasts will be performed to test the potential role of 
cellular proliferation in iCM reprogramming. 
In summary, the icMEF cell line described here will facilitate high-throughput and combinatorial 
screening using libraries of small molecules, pharmacological reagents, and non-coding RNAs to further 
accelerate research in the field. The rapid and simple single GFP reporter read-out is ideal for such 
purposes since it reduces potential noise and complications from additional markers. Primary screening 
using the icMEF cell line has the advantage of high throughput and high yield but can inevitably yield 
false positives. Because icMEF is a transformed fibroblast cell line, icMEFs cannot be reprogrammed into 
fully matured, beating cardiomyocytes. Candidate factors identified from large screens in icMEFs will 
need to be validated and further characterized through secondary screens in primary fibroblasts using 
additional read-outs, including supplemental markers and functional parameters. The icMEF cell line was 
designed as a tool for the rapid, high-throughput identification of novel factors involved iCM 
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CHAPTER 3: CHARACTERIZATION OF EPIGENETIC BARRIERS DURING DIRECT CARDIAC 
REPROGRAMMING3 
Introduction 
Epigenetic Changes During Reprogramming 
At its very heart, direct cardiac reprogramming is an epigenetic process. Massive transcriptional 
changes are required when reprogramming cells turn off the expression of genes associated with their 
fibroblast identity and turn on cardiomyocyte cell fate genes (Figure 3.1A). Since epigenetic 
modifications govern chromatin structure and transcriptional status, these massive transcriptional 
changes are preceded by widespread epigenetic repatterning. Using genome-wide analysis, Zhao et al. 
show that reprogramming cells lose fibroblast-specific H3K4me2 peaks (which mark promoters and 
enhancers of transcriptionally active genes) and acquire H3K4me2 peaks that are specific to primary 
neonatal mouse ventricular cardiomyocytes (Zhao et al., 2015). Liu et al. show that the transcriptionally 
repressive histone mark H3K27me3 is depleted at cardiac promoters while the transcriptionally active 
histone mark H3K4me3 is enriched at cardiac promoters and is accompanied by a rapid increase in 
cardiac gene mRNA expression early during the reprogramming process (Liu et al., 2016b). 
Subsequently, the transcriptionally repressive histone mark H3K27me3 is increased and the 
transcriptionally active histone mark H3K4me3 is decreased at fibroblast loci, accompanied by a 
corresponding decrease in fibroblast gene mRNA expression (Liu et al., 2016b). Dal-Pra et al. show that 
the transcriptionally repressive histone mark H3K27me3 is globally depleted during reprogramming (Dal-
Pra et al., 2017). Moreover, H3K27me3 is specifically depleted at the promoters of cardiac transcription 
 
3 Chapter 3 Figures 3.7-3.11 were published in a research article in Cell Stem Cell. Its formal citation is: Zhou, Y., 
Wang, L., Vaseghi, H.R., Liu, Z., Lu, R., Alimohamadi, S., Yin, C., Fu, J.-D., Wang, G.G., Liu, J., et al. (2016). Bmi1 Is a 
Key Epigenetic Barrier to Direct Cardiac Reprogramming. Cell Stem Cell 18, 382–395. 
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factors Tbx5, Mef2c, and Gata4 (Dal-Pra et al., 2017). Reprogramming alters the expression of histone 
methyltransferases and demethylases which regulate the transcriptionally repressive histone mark 
H3K27me3 (Dal-Pra et al., 2017). Reprogramming upregulates the expression of two H3K27 
demethylases Kdm6A and Kdm6B and represses the expression of the H3K27 methyltransferase Ezh2 
(Dal-Pra et al., 2017). These findings indicate that widespread epigenetic repatterning, particularly the 
depletion of H3K27me3-mediated transcriptional repression, occurs during reprogramming.  
Polycomb Repressive Complex 2 
The trimethylation of Histone 3 at Lysine 27 (H3K27me3) is a transcriptionally repressive histone 
posttranslational modification that is catalyzed by the Polycomb Repressive Complex 2 (PRC2) 
(Margueron and Reinberg, 2011; Surface et al., 2010). The PRC2 is comprised of the histone 
methyltransferase Ezh1 or Ezh2 and core components Eed and Suz12, which are involved in holoenzyme 
recruitment and stability (Ho and Crabtree, 2008; Sauvageau and Sauvageau, 2010) (Figure 3.1B). Ezh1 
and Ezh2 are SET domain containing methyltransferases which catalyze H3K27 di- and tri-methylation 
(Ho and Crabtree, 2008). Ezh1 may compensate for Ezh2 loss of function, but studies indicate that Ezh1 
and Ezh2 maintain PRC2-mediated transcriptional repression through different mechanisms (He et al., 
2012; Ho and Crabtree, 2008; Margueron et al., 2008; Shen et al., 2008). H3K27me3 forms a docking site 
for the Polycomb Repressive Complex 1 (PRC1) which monoubiquinates Histone 2A at Lysine 119 
(H2AK119ub), resulting in gene silencing and chromatin compaction (Ho and Crabtree, 2008; Margueron 
and Reinberg, 2011; Surface et al., 2010) (Figure 3.1B). H3K27 methylation suppresses non-lineage gene 
expression (Delgado-Olguín et al., 2012; Surface et al., 2010). PRC1 and PRC2 directly repress 
developmental regulators (Boyer et al., 2006). In embryonic stem cells, PRC1 and PRC2 co-occupy 512 
genes, all of which are epigenetically modified with H3K27me3 (Boyer et al., 2006). Of these repressed 
genes, 203 are transcription factors, including Tbx5 and Gata4 (Boyer et al., 2006). These findings 
indicate that the epigenetic modifier PRC2 may pose a barrier to direct cardiac reprogramming.  
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Experimental Evidence for the Role of PRC2 in Reprogramming 
We expect that inhibiting PRC2 activity will de-repress cardiac loci, facilitate chromatin 
accessibility to reprogramming cocktail cardiac transcription factors, and enhancing reprogramming. 
Indeed, Dal-Pra et al. show that pharmacological inhibition of H3K27 methyltransferase activity using 
the S-adenosylmethionine-dependent methyltransferase inhibitor 3-Deazaneplanocin A (DZNep) 
reduced global H3K27me3 and increased cardiac transcription factor expression in reprogramming cells 
(Dal-Pra et al., 2017). Intriguingly, DZNep upregulated the expression of cardiac transcription factors and 
cardiac genes in unreprogrammed fibroblasts (Dal-Pra et al., 2017). DZNep did not, however, further 
increase cardiac gene expression in cells reprogrammed with a microRNA (miR) cocktail (Dal-Pra et al., 
2017). RNA interference knockdown of Eed, a core component of the PRC2, reduced global H3K27me3 
and increased cardiac transcription factor expression (Dal-Pra et al., 2017). However, RNA interference 
knockdown of Eed, Ezh1, or Ezh2 did not further increase reprogramming efficiency of the miR cocktail 
(Dal-Pra et al., 2017). Another study used the pharmacological inhibitor GSK126 to inhibit Ezh2 activity 
during reprogramming with a transcription factor cocktail (Hirai and Kikyo, 2014). GSK126 is a small 
molecule inhibitor that is selective for Ezh2 over Ezh1 with 150-fold decreased potency for Ezh1 
(McCabe et al., 2012). Hirai et al. found that the Ezh2 specific inhibitor GSK126 has different effects 
when administered at different times during the reprogramming process (Hirai and Kikyo, 2014).  
Polycomb Repressive Complex 1 
The Polycomb Repressive Complex 1 (PRC1) monoubiquinates Histone 2A at Lysine 119 
(H2AK119ub), resulting in gene silencing and chromatin compaction (Ho and Crabtree, 2008; Margueron 
and Reinberg, 2011; Surface et al., 2010) (Figure 3.1B). The PRC1 holoenzyme involves three ring 
domain-containing proteins: Ring1A, Ring1B, and Bmi1 (Cao et al., 2005). Bmi1 is a key component of 
PRC1, playing an essential role in PRC1 assembly and H2AK119 ubiquitination (Cao et al., 2005; Ku et al., 
2008; Morey et al., 2015). Bmi1 functions in PRC1 as a transcriptional repressor, ubiquitinating Histone 
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2A Lysine 119 to cause chromatin compaction (Park et al., 2004). PRC1 directly represses developmental 
regulators, including the cardiac lineage transcription factors Tbx5 and Gata4 (Boyer et al., 2006), 
suggesting that PRC1 may function as an epigenetic barrier to direct cardiac reprogramming. 
Bmi1 and Cellular Proliferation 
Bmi1 is best known for its regulation of cellular proliferation and senescence through its 
suppression of target genes p16Ink4a, p19ARF, and p53 (Park et al., 2004). This suppression induces cell 
cycle progression and cellular proliferation (Park et al., 2004). Thus, Bmi1 deficiency prevents cells from 
proliferating, making them senescent, while Bmi1 overexpression immortalizes cells (Jacobs et al., 1999) 
Materials and Methods 
Cardiac Reprogramming Using αMHC-GFP MEF. 
Mouse embryonic fibroblasts (MEF) were isolated as previously described (Jozefczuk et al., 
2012) from αMHC-GFP reporter mice (Ieda et al., 2010; Qian et al., 2012). Animal care was performed in 
accordance with the guidelines established by University of North Carolina, Chapel Hill. One day prior to 
infection, MEF were seeded at a density of 2x104 cells per well in 24 well plates coated with 0.01% 
gelatin. Polycistronic MGT reprogramming cocktail retrovirus was packaged as described previously 
(Wang et al., 2015b). Precipitated retrovirus was resuspended in iCM media (4:1 DMEM:M199 with 10% 
FBS) with 1 ug/mL polybrene and added to cells. Each well of a 24 well plate was treated with 
resuspended retrovirus equivalent to 1/10th of the viral production of a 10cm dish. Three days post 
infection, cells were selected with 2 ug/mL Puromycin in the media for three days.  
Flow Cytometry 
Cells were dissociated with 0.025% Trypsin-EDTA, washed and resuspended in PBS. Cells were 
fixed and permeabilized in Cytofix/Cytoperm Solution (BD Biosciences) for 20 minutes at 4°C. After 
washing, cells were stained with primary antibody against GFP (1:500, Thermo Fisher Scientific) for 30 
minutes at 4°C, washed, and stained with secondary antibody anti-rabbit AlexaFluor 488 (1:500, Jackson 
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Immuno Research). Cells were washed and resuspend in PBS for analysis by flow cytometry. Data was 
collected on a CyAn ADP high-speed analyzer (Beckman Coulter) and analyzed using FlowJo software 
(Tree Star). 
Western Blotting. 
Cells were lysed in 2x SDS loading buffer (Bio-Rad). Proteins in cell lysate was separated by SDS-
PAGE, transferred to nitrocellulose membranes, blocked in 5% milk, and probed with antibody against 
H3K27me3 (1:1000, ActiveMotif). The target proteins were detected by chemiluminescence (ECL, 
Thermo Fisher Scientific). The membranes were stripped with stripping buffer (Sigma) and re-probed 
with antibody against total H3 (1:1000, ActiveMotif) as a loading control. 
Real Time Quantitative Polymerase Chain Reaction. 
Total RNA was harvested from cells by standard phenol/chloroform isolation using TRIzol 
reagent (Thermo Fisher Scientific). cDNA was obtained by SuperScript III Reverse Transcriptase (Thermo 
Fisher Scientific) according to the manufacturer’s protocol. RT-qPCR was performed on a ViiA 7 Real-
Time PCR System (Applied Biosystems) with SYBR Green (Thermo Fisher Scientific) chemistry. 
Statistical Analyses. 
Where appropriate, values are expressed as the mean ± standard deviation of triplicate 
experiments. Statistical analyses were performed with one-way or two-way analyses of variance 
followed by Bonferroni correction. A P value of < 0.05 was considered statistically significant (*), a P 
value of < 0.01 was considered highly significant (**), and a P value of < 0.001 was considered strongly 
significant (***). All data are representative of multiple repeated experiments. 
Results 
PRC2 subunit depletion does not enhance reprogramming. 
We hypothesize that transcriptional repression mediated through the epigenetic modifier PRC2 
is a barrier to direct cardiac reprogramming. Therefore, we expect that inhibiting PRC2 will enhance 
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direct cardiac reprogramming. To test whether PRC2 functions as a barrier to reprogramming, we used 
short hairpin RNA (shRNA) to knockdown key subunits of PRC2 during the reprogramming process. We 
infected cardiac reporter αMHC-GFP mouse embryonic fibroblasts (MEF) with polycistronic MGT 
reprogramming retrovirus and shRNA lentivirus. After eleven days, reprogramming efficiency was 
assessed by flow cytometry for GFP. We pooled five different shRNA lentiviruses targeting each subunit. 
As a negative control, we used a non-targeting shRNA control lentivirus (shNT) by packaging MISSION 
pLKO.1-puro Non-Mammalian shRNA Control Plasmid DNA, which does not target any known 
mammalian genes. Since we previously showed that Bmi1, a PRC1 subunit, functions as an epigenetic 
barrier to reprogramming (Zhou et al., 2016), we included shRNA lentivirus targeting Bmi1 (shBmi1) as a 
positive control. Although Bmi1 knockdown enhances reprogramming, knockdown of PRC2 subunits 
Ezh1, Ezh2, Eed, or Suz12 does not enhance reprogramming (Figure 3.2). 
Simultaneous depletion of Ezh1 and Ezh2 does not enhance reprogramming. 
Since Ezh1 and Ezh2 can both function as the catalytic subunit of PRC2 it is possible that one 
may compensate for loss of function in the other. To test reciprocal compensation, we performed 
RTqPCR for Ezh1 and Ezh2 transcript expression two days after shRNA knockdown in mouse embryonic 
fibroblasts. We found that Ezh1 expression is increased when Ezh2 is knocked down and that Ezh2 
expression is increased when Ezh1 is knocked down (Figure 3.3A and B), suggesting that Ezh1 and Ezh2 
compensate for each other. We then knocked down both Ezh1 and Ezh2 simultaneously during 
reprogramming but found that double knockdown does not enhance reprogramming (Figure 3.3C). 
Pharmacological inhibition of Ezh1/2 reduces H3K27me3 but does not enhance reprogramming. 
In addition to our RNA interference approach, we used a pharmacological approach to inhibiting 
PRC2 function. The pharmacological inhibitor UNC1999 inhibits enzymatic activity of both Ezh1 and Ezh2 
(Konze et al., 2013). We performed a dose curve of UNC1999 to find the optimal dosage to inhibit PRC2 
activity. We incubated mouse embryonic fibroblasts with a range of concentrations of UNC1999 or the 
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vehicle control DMSO for six days and performed a western blot probing for H3K27me3 and total H3 
(Figure 3.4A). We found that UNC1999 depletes H3K27me3 proportionally to the concentration. While 
10 nM UNC1999 did not reduce the H3K27me3, 100 nM UNC1999 depleted H3K27me3 by 50% 
compared to the DMSO control and 1000 nM UNC1999 depleted H3K27me3 by 90%. We then used 
these three concentrations of UNC1999 to provide a range of PRC2 inhibition during the reprogramming 
process. We infected αMHC-GFP MEF with polycistronic MGT reprogramming retrovirus and treated 
them with UNC1999 or DMSO vehicle control. After ten days, reprogramming efficiency was assessed by 
flow cytometry for GFP. Although 1000 nM UNC1999 was sufficient to significantly deplete H3K27me3, 
it did not increase reprogramming efficiency, indicating that Ezh1/2 catalytic activity does not function 
as a barrier to reprogramming (Figure 3.4B). 
Pharmacological inhibition of Ezh1/2 does not alter early reprogramming events. 
During reprogramming, epigenetic re-patterning and cardiac gene expression changes are seen 
as early as the third day of reprogramming (Liu et al., 2016b). We asked whether the effects of Ezh1/2 
inhibition could be seen early in reprogramming at the third and fifth day. Reprogramming mouse 
embryonic fibroblasts were treated with high, mid, and low dose UNC1999. Reprogramming efficiency 
was assessed by flow cytometry for GFP at the third, fifth, and tenth day after reprogramming (Figure 
3.5). Inhibition of Ezh1/2 catalytic activity does not increase reprogramming at early stages (Figure 3.5). 
Pharmacological inhibition of Ezh2 does not increase reprogramming. 
Hirai et al. showed previously that the Ezh2 specific inhibitor GSK126 has different effects when 
administered at different times during the reprogramming process (Hirai and Kikyo, 2014). GSK126 
inhibitor treatment from reprogramming day two through eight (D2-8) had no effect. GSK126 inhibitor 
treatment from D4-8 repressed reprogramming, while treatment from D2-5 increased reprogramming 
(Hirai and Kikyo, 2014). To validate these findings in our experimental model, we treated 
reprogramming mouse embryonic fibroblasts with GSK126 at the same dose used by Hirai et al. and 
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during the same time periods. We found that GSK126 does not increase reprogramming at D2-5 in our 
experimental system (Figure 3.6B and C). GSK126 is a small molecule inhibitor that is selective for Ezh2 
over Ezh1 with 150-fold decreased potency for Ezh1 (McCabe et al., 2012). UNC1999 has potency and 
selectivity for both Ezh1 and Ezh2 (Konze et al., 2013). Neither UNC1999 nor GSK126 increased 
reprogramming compared to a vehicle control for any length of administration tested (Figure 3.6C). 
Loss-of-function screen identifies epigenetic regulators likely to function as barriers to reprogramming.  
Our findings did not indicate that the PRC2 functions as an epigenetic barrier to reprogramming; 
however, given the pivotal role of epigenetics in cellular transdifferentiation (Figure 3.1A), it seems likely 
that other epigenetic modifiers may affect reprogramming. We therefore conducted the first reported 
loss-of-function screen for epigenetic barriers to reprogramming using shRNA targeting 35 components 
of chromatin modifying or remodeling complexes (Figure 3.7). We discovered numerous factors that 
acted as barriers to reprogramming. Silencing these factors enhanced reprogramming. Of these factors, 
we found that depleting the polycomb ring finger oncogene Bmi1 resulted in a ten-fold enhancement of 
reprogramming (Figure 3.7). This loss-of-function screen also confirms our previous findings that 
depleting subunits of the PRC2 fails to enhance reprogramming. 
Bmi1 depletion does not enhance reprogramming through de-repressing cell cycle regulators.  
Bmi1 is well known for its regulation of cellular proliferation through its suppression of tumor 
suppressors p16Ink4a, p19ARF, and p53 (Park et al., 2004). By suppressing these genes, Bmi1 induces cell 
cycle progression and cellular proliferation (Park et al., 2004). Bmi1 deficiency de-represses these tumor 
suppressors and induces cellular senescence (Jacobs et al., 1999). We therefore asked whether silencing 
Bmi1 enhances reprogramming by repressing cellular proliferation. We found that, indeed, Bmi1 
knockdown increases gene expression of p16Ink4a, p19ARF, and p53 (Figure 3.8A). However, independently 
silencing expression of p16Ink4a, p19ARF, or p53 did not reverse Bmi1 depletion’s enhancement of 
reprogramming (Figure 3.8B and C). We also performed double and triple knockdowns of p16Ink4a, 
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p19ARF, or p53 to rule out compensatory mechanisms (Figure 3.8D and E). We conclude that the 
reprogramming enhancement caused by Bmi1 depletion is not mediated through de-repression of 
Bmi1’s downstream effectors involved in cellular proliferation. 
Inhibiting cellular proliferation does not reverse the Bmi1 depletion phenotype. 
In an alternative approach, we used Mitomycin C (MMC) to inhibit cellular proliferation. 
Mitomycin C is a DNA interstrand cross-linking agent (Grillari et al., 2007) that causes drug-induced 
accelerated senescence in cells (Alili et al., 2014). Given that Bmi1 activity positively regulates cell cycle 
progression and that Bmi1 depletion causes cellular senescence, we asked whether Bmi1 depletion 
enhances reprogramming by repressing cellular proliferation. We inhibited cellular proliferation with 
MMC two days after reprogramming and assessed reprogramming efficiency by flow cytometry for 
cardiac markers at reprogramming day 10 (Figure 3.9A). We found that in both proliferating cells 
(untreated) and cell cycle arrested cells (MMC treated), Bmi1 knockdown enhances reprogramming 
similarly (Figure 3.9B and C). If Bmi1 depletion enhances reprogramming by inducing cellular 
senescence, we would expect to see no difference between shBmi1 and control shNT treated cells in the 
MMC treated condition, where all cells are senescent. However, we found that merely inducing cellular 
senescence was not sufficient to recapitulate the Bmi1 knockdown phenotype (Figure 3.9B and C). 
To further validate these findings, we used nucleotide analog incorporation to label senescent 
cells. We inhibited proliferation with MMC as before and labeled proliferating cells with the nucleotide 
analog EdU, assessing reprogramming efficiency and EdU incorporation using flow cytometry at 
reprogramming day 10 (Figure 3.9D). Proliferating cells incorporate the nucleotide analog EdU into 
newly synthesized DNA, while senescent cells remain EdU negative. We found that Bmi1 knockdown 
enhances reprogramming compared to the control shNT knockdown in the EdU negative senescent cell 
population (Figure 3.9E and F). These findings support our conclusion that Bmi1 depletion enhances 
reprogramming through a proliferation-independent mechanism. 
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Bmi1 knockdown primes cells for reprogramming. 
Given that chromatin remodeling is a prerequisite step in cellular transdifferentiation, we asked 
whether removing epigenetic barriers prior to reprogramming could enhance reprogramming. We 
depleted Bmi1 in cardiac fibroblasts for three days before introduction of the polycistronic MGT 
reprogramming cocktail (Figure 3.10A) and found that Bmi1 depletion primes fibroblasts for 
reprogramming. 
Inhibiting Bmi1 can replace Gata4 in the reprogramming cocktail.  
Bmi1 ChIP-seq performed by our lab indicates that Bmi1 directly binds to the regulatory region 
of Gata4 and represses its expression (Zhou et al., 2016). We therefore asked if Bmi1 depletion can de-
repress endogenous Gata4 expression and functionally replace exogenous reprogramming cocktail 
Gata4 expression during reprogramming. We used short hairpin RNA interference knockdown of Bmi1 
(shBmi1) in conjunction with a bicistronic Mef2c-Tbx5 reprogramming cocktail and found that this 
Mef2c/Tbx5/shBmi1 combination is sufficient to reprogram fibroblasts into iCMs (Figure 3.11A and B). 
Furthermore, we showed that short hairpin RNA interference knockdown of Gata4 reverses this effect 
(Figure 3.11A and B), demonstrating that Bmi1 depletion de-represses endogenous Gata4 expression in 
reprogramming cells. In summary, we found that Bmi1 depletion de-represses endogenous Gata4 







Figure 3.1. Direct Cardiac Reprogramming is an Epigenetic Process. A) When reprogramming fibroblasts 
into cardiomyocytes, cells must turn off prior fibroblast gene expression program and turn on a 
cardiomyocyte gene expression program. B) PRC1 and PRC2 post-translationally modify histones to 




Figure 3.2. Silencing subunits of the PRC2 does not increase reprogramming. Reprogramming efficiency 
quantified by flow cytometry for αMHC-GFP at reprogramming D11 and expressed as the percentage of 
cTnT+ cells. Mouse embryonic fibroblasts from αMHC-GFP cardiac reporter mice were infected with 
MGT polycistronic reprogramming cocktail retrovirus at D0 and shRNA lentiviruses at D1. Non-targeting 






Figure 3.3. Silencing PRC2 catalytic activity does not increase reprogramming. A) Ezh1 gene expression 
quantified by RTqPCR. Ezh1 knockdown (shEzh1) reduces Ezh1 mRNA expression while Ezh2 knockdown 
(shEzh2) increases Ezh1 mRNA expression. B) Ezh2 gene expression quantified by RTqPCR. Ezh1 
knockdown increases Ezh2 mRNA expression while Ezh2 knockdown reduces Ezh2 mRNA expression. C) 
Double knockdown of Ezh1 and Ezh2 does not enhance reprogramming. Reprogramming efficiency 
quantified by flow cytometry for cardiac reporter αMHC-GFP at reprogramming D10 and expressed as 
the percentage of αMHC-GFP + cells. Mouse embryonic fibroblasts from αMHC-GFP cardiac reporter 
mice were infected with MGT polycistronic reprogramming cocktail retrovirus at D0 and shRNA 





Figure 3.4. Pharmacological inhibition of PRC2 catalytic activity does not increase reprogramming. A) 
Ezh1/2 inhibitor UNC1999 reduces global H3K27me3. Histone 3 Lysine 27 trimethylation (H3K27me3) 
quantified by western blot. Mouse embryonic fibroblasts were treated with varying concentrations of 
UNC1999 or DMSO vehicle control for 6 days. B) Ezh1/2 inhibitor UNC1999 does not increase 
reprogramming. Mouse embryonic fibroblasts from αMHC-GFP cardiac reporter mice were infected with 
MGT polycistronic reprogramming cocktail retrovirus at reprogramming D0. Reprogramming cells were 
treated with 10 nM UNC1999, 100 nM UNC1999, 1000 nM UNC1999, or DMSO vehicle control 
continuously starting at D0. Reprogramming efficiency was determined by flow cytometry for the 







Figure 3.5. Pharmacological inhibition of Ezh1/2 does not accelerate reprogramming. Ezh1/2 inhibitor 
UNC1999 does not accelerate early acquisition of cardiac reporter αMHC-GFP. Mouse embryonic 
fibroblasts from αMHC-GFP cardiac reporter mice were infected with MGT polycistronic reprogramming 
cocktail retrovirus at reprogramming D0. Reprogramming cells were treated with 10 nM UNC1999, 100 
nM UNC1999, 1000 nM UNC1999, or DMSO vehicle control continuously from D0. Reprogramming 
efficiency was determined by flow cytometry for the cardiac reporter αMHC-GFP at reprogramming D3, 





Figure 3.6. Pharmacological inhibition of Ezh2 does not enhance reprogramming. A) Schematic of the 
experiment design. Mouse embryonic fibroblasts from αMHC-GFP cardiac reporter mice were infected 
with MGT polycistronic reprogramming cocktail retrovirus at reprogramming D0. Reprogramming cells 
were treated with 1 uM GSK126, 1 uM UNC1999, or DMSO vehicle control from reprogramming D2 to 
D5, D2 to D8, or D4 to D8. Reprogramming efficiency was determined by flow cytometry for the cardiac 
reporter αMHC-GFP at reprogramming D10.  B) Ezh2 inhibitor GSK126 does not increase reprogramming 
for any window of drug administration. C) Neither Ezh1/2 inhibitor UNC199 nor Ezh2 inhibitor GSK126 





Figure 3.7. Loss-of-function screen identifies epigenetic regulators likely to function as barriers to 
reprogramming. Reprogramming efficiency quantified by flow cytometry for cardiac reporters αMHC-
GFP and cTnT and expressed as the fold change in percent marker positive cells for each shRNA 
treatment over non-targeting shRNA (shNT) control. Neonatal cardiac fibroblasts from αMHC-GFP 





Figure 3.8. Bmi1 depletion’s enhancement of reprogramming is not mediated through cell cycle 
regulators. A) Tumor suppressor gene expression quantified by RTqPCR. Neonatal cardiac fibroblasts 
from αMHC-GFP cardiac reporter mice were infected with MGT polycistronic reprogramming cocktail 
retrovirus and shRNA lentivirus. Non-targeting shRNA (shNT) was used as a negative control. B) 
Reprogramming efficiency quantified by flow cytometry for cardiac reporter αMHC-GFP and expressed 
as the fold change in percent αMHC-GFP+ cells for shBmi1 treatment over non-targeting shRNA (shNT) 
control. Neonatal cardiac fibroblasts from αMHC-GFP mice were infected with MGT polycistronic 
reprogramming cocktail retrovirus and shRNA lentivirus. C) Reprogramming efficiency quantified by flow 
cytometry for cardiac reporter cTnT and expressed as the fold change in percent cTnT+ cells for shBmi1 
treatment over non-targeting shRNA (shNT) control. D) Reprogramming efficiency quantified by flow 
cytometry for cardiac reporter αMHC-GFP and expressed as the fold change in percent αMHC-GFP+ cells 
for shBmi1 treatment over non-targeting shRNA (shNT) control. E) Reprogramming efficiency quantified 
by flow cytometry for cardiac reporter cTnT and expressed as the fold change in percent cTnT+ cells for 




Figure 3.9. Inhibiting cellular proliferation does not abrogate Bmi1 depletion’s enhancement of 
reprogramming. A) Schematic of the experimental design. Neonatal cardiac fibroblasts were infected 
with MGT polycistronic reprogramming cocktail retrovirus and shRNA lentivirus. Bmi1 knockdown 
lentivirus (shBmi1); non-targeting control lentivirus (shNT). Two days later, cells were treated with 
Mitomycin C (MMC) to inhibit cellular proliferation. Reprogramming efficiency was quantified by flow 
cytometry at day 10. B) Reprogramming efficiency quantified by flow cytometry for cardiac reporter 
αMHC-GFP and expressed as the fold change in percent αMHC-GFP+ cells for shBmi1 treatment over 
shNT control. Mitomycin C (MMC); untreated (UT). C) Reprogramming efficiency quantified by flow 
cytometry for cardiac reporter cTnT and expressed as the fold change in percent cTnT+ cells for shBmi1 
treatment over shNT control. Mitomycin C (MMC); untreated (UT). D) Schematic of experimental design. 
Neonatal cardiac fibroblasts were infected with MGT polycistronic reprogramming cocktail retrovirus. 
The next day, cells were treated with Mitomycin C (MMC) to inhibit cellular proliferation and infected 
with shRNA lentivirus. Bmi1 knockdown lentivirus (shBmi1); non-targeting control lentivirus (shNT). Cells 
were incubated with nucleotide analog EdU at day 2 (F) or day 8 (E). Reprogramming efficiency was 
quantified by flow cytometry at day 10. E) Reprogramming efficiency quantified by flow cytometry for 
cardiac reporter αMHC-GFP and expressed as the fold change in percent αMHC-GFP+ cells of EdU- cells 
for shBmi1 treatment over shNT control. F) Reprogramming efficiency quantified by flow cytometry for 
cardiac reporter cTnT and expressed as the fold change in percent cTnT+ cells of EdU- cells for shBmi1 
treatment over shNT control.  
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Figure 3.10. Bmi1 depletion primes cells for reprogramming. A) Schematic of experimental design. 
Neonatal cardiac fibroblasts were infected shRNA lentivirus at reprogramming D-4. Bmi1 knockdown 
lentivirus (shBmi1); non-targeting control lentivirus (shNT). Cells were selected with Puromycin starting 
at reprogramming D-3. Cells were reseeded into new cell culture dishes at D-1. Cells were infected with 
MGT polycistronic reprogramming cocktail retrovirus at D0. Reprogramming efficiency was quantified by 
flow cytometry at D10.  B) Reprogramming efficiency quantified by flow cytometry for cardiac reporter 
αMHC-GFP and cTnT and expressed as the fold change in percent marker positive cells for shBmi1 




Figure 3.11. Bmi1 depletion can substitute for Gata4 factor expression in the reprogramming cocktail. 
A) Reprogramming efficiency quantified by flow cytometry for cardiac reporter αMHC-GFP and 
expressed as the fold change in percent αMHC-GFP+ cells for shBmi1 treatment over shNT control. 
Neonatal cardiac fibroblasts from αMHC-GFP cardiac reporter mice were infected with Mef2c-Tbx5 (MT) 
reprogramming cocktail retrovirus and shRNA lentivirus. Bmi1 knockdown lentivirus (shBmi1); Gata4 
knockdown lentivirus (shGata4) non-targeting control lentivirus (shNT and shTubo). B) Reprogramming 
efficiency quantified by flow cytometry for cardiac reporter cTnT and expressed as the fold change in 
percent cTnT+ cells for shBmi1 treatment over shNT control. Neonatal cardiac fibroblasts from αMHC-
GFP cardiac reporter mice were infected with Mef2c-Tbx5 (MT) reprogramming cocktail retrovirus and 
shRNA lentivirus. Bmi1 knockdown lentivirus (shBmi1); Gata4 knockdown lentivirus (shGata4) non-





Since H3K27me3 is depleted at cardiac loci and PRC2 target genes are de-repressed during 
reprogramming, we hypothesized that PRC2 mediated transcriptional repression functions as a barrier 
to direct cardiac reprogramming. We therefore expected that the inhibition of PRC2 would enhance 
direct cardiac reprogramming. However, we found that inhibiting PRC2 does not improve direct cardiac 
reprogramming speed or conversion efficiency. We used a dual approach of pharmacological inhibitors 
and RNA interference to inhibit PRC2 activity. Both shRNA knockdown of PRC2 components and 
pharmacologic inhibition of PRC2 catalytic activity fail to increase reprogramming. We conclude that 
PRC2 does not form a substantial epigenetic barrier to reprogramming.  
Similarly to Dal-Pra et al., we found that PRC2 inhibition depletes H3K27me3 but does not 
enhance direct cardiac reprogramming. Conversely to Hirai et al., we did not find that GSK126 inhibitor 
treatment from D2-5 increased reprogramming. There are several key differences between our study 
and that of Hirai et al., including the starting fibroblast cell type, the reprogramming cocktail used, the 
quantification of reprogramming, and experimental controls. Hirai et al. reprogrammed mouse 
embryonic fibroblasts derived from the heads of mouse embryos (Hirai and Kikyo, 2014), while we 
reprogrammed mouse embryonic fibroblasts derived from mouse embryos after the head and organs 
had been dissected out (Jozefczuk et al., 2012). Hirai et al. used a MM3-GHT reprogramming cocktail 
(Hirai and Kikyo, 2014), while we used our polycistronic MGT reprogramming cocktail (Wang et al., 
2015a). Hirai et al. assessed reprogramming efficiency by counting beating colonies at reprogramming 
D14 (Hirai and Kikyo, 2014), while we assessed reprogramming efficiency by flow cytometry for the 
cardiac reporter αMHC-GFP at reprogramming D10. Crucially, Hirai and Kikyo did not include a vehicle 
control in their experiments, while we included a DMSO vehicle control which made a significant 
difference in our data analysis. 
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While we did not find that Ezh2 functions as an epigenetic barrier to reprogramming, we did 
demonstrate that the epigenetic modulator Bmi1 functions as a barrier to reprogramming. Bmi1 does 
not inhibit reprogramming through its canonical role regulating cell cycle and proliferation. Instead, 
Bmi1 depletion de-represses endogenous Gata4 expression such that Bmi1 depletion can replace 
exogenous Gata4 in the reprogramming cocktail, allowing for reprogramming with a two-factor Mef2c-





CHAPTER 4: STUDYING MITOCHONDRIAL DYNAMICS DURING DIRECT CARDIAC 
REPROGRAMMING 
Introduction 
Cardiomyocyte Mitochondria  
Cardiomyocytes have enormous energy requirements. The human heart consumes around 30 kg 
of ATP (roughly 100 times its own weight) daily (Dorn, 2013). Most of this energy is produced by the 
mitochondria within the cardiomyocytes. Mitochondria fill an estimated 30% of the volume of a 
ventricular cardiomyocyte (Dorn, 2013; Piquereau et al., 2013). Clusters of round subsarcolemmal 
mitochondria are connected by intermitochondrial junctions directly beneath the cell membrane 
(Skulachev, 2001). The subsarcolemmal mitochondria receive oxygen from the cell surface and use the 
electron transport chain to generate a proton gradient in the mitochondrial intermembrane space 
(Skulachev, 2001). This electrochemical potential diffuses through conjoined mitochondria to reach the 
interfibrillar mitochondria (Skulachev, 2001). Chains of ellipsoid interfibrillar mitochondria are aligned 
between myofibrils deep into the cardiomyocyte (Dorn, 2013; Skulachev, 2001). The interfibrillar 
mitochondria use proton-motive force to generate ATP and power cardiomyocyte contraction. The 
entire cardiomyocyte mitochondrial network is connected by intermitochondrial junctions (Skulachev, 
2001). In this division of labor, subsarcolemmal mitochondria are primarily responsible for respiration 
while interfibrillar mitochondria generate the majority of the ATP. Although mitochondrial movement is 
restricted by the dense intracellular architecture of cardiomyocytes (Piquereau et al., 2013), 
mitochondrial fusion is required for mitochondrial function (Chen et al., 2011b; Dorn, 2013) and 





Mitochondrial morphology is restructured through fusion and fission processes. Mitochondria 
are dynamic organelles whose morphology ranges from fused networks to isolated fragments. 
Morphology is linked to function. In general, fragmented mitochondria are associated with reduced 
metabolic demand while fused mitochondrial networks are associated with metabolically active cells. 
(Piquereau et al., 2013; Wai and Langer, 2016; Westermann, 2012). Key proteins regulate these fission 
and fusion events. Mfn1, Mfn2, and Opa1 regulate mitochondrial membrane fusion, while Fis1 and Drp1 
mediate mitochondrial fission (Wai and Langer, 2016) (Figure 4.3A). Mitochondrial fusion is required for 
cardiomyocyte differentiation and maturation during embryonic development. The cardiomyocytes of 
E9.5 mouse embryos have few, fragmented, immature mitochondria (Hom et al., 2011). By E13.5, these 
cardiac mitochondria have matured and fused into elongated and branching mitochondrial networks 
(Hom et al., 2011). Moreover, the expression of genes associated with mitochondrial fission, including 
Drp1 (also known as Dnm1l), are downregulated during embryonic stem cell cardiac differentiation 
while the expression of genes associated with mitochondrial fusion, including Mfn2, are upregulated 
(Chung et al., 2007). We therefore asked whether iCM reprogramming increases intracellular 
mitochondria number and whether manipulating mitochondrial morphology can affect reprogramming 
outcomes. 
Materials and Methods 
Cardiac Reprogramming Using Freshly Isolated Neonatal Mouse Cardiac Fibroblasts. 
Neonatal mouse cardiac fibroblasts were isolated as previously described (Wang et al., 2015b) 
from CD1 mice (Ieda et al., 2010; Qian et al., 2012). Animal care was performed in accordance with the 
guidelines established by University of North Carolina, Chapel Hill. One day prior to infection, fibroblasts 
were seeded at a density of 5x104 cells per well in 24 well plates coated with 0.01% gelatin. Polycistronic 
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MGT reprogramming cocktail retrovirus or LacZ control retrovirus were packaged as described 
previously (Wang et al., 2015b). Precipitated retrovirus was resuspended in iCM media (4:1 
DMEM:M199 with 10% FBS) with 1 ug/mL polybrene and added to cells. Each well of a 24 well plate was 
treated with resuspended MGT or LacZ retrovirus equivalent to 1/5th of the viral production of a 10cm 
dish. Three days post infection, cells were selected with 2 ug/mL Puromycin in the media for three days. 
Mitochondrial DNA qPCR. 
Cell cultures in 24 well plates were dissociated with 0.025% Trypsin-EDTA. DNA was isolated 
using a Gentra Puregene Cell Kit (Qiagen) according to the manufacturer’s instructions. Quantitative PCR 
was performed on a ViiA 7 Real-Time PCR System (Applied Biosystems) with SYBR Green (Thermo Fisher 
Scientific) chemistry. 
MitoTracker Flow Cytometry. 
Cell cultures in 24 well plates were washed with warm DMEM and loaded with 200 nM 
MitoTracker Red CMXRos (Invitrogen) at 37°C for 30 minutes. Cells were washed with DMEM and PBS 
before dissociation with 0.025% Trypsin-EDTA. Trypsin was quenched with 10% FBS in PBS. Cells were 
centrifuged and resuspended in PBS for immediate analysis by flow cytometry. Data was collected on a 
CyAn ADP high-speed analyzer (Beckman Coulter) and analyzed using FlowJo software (Tree Star). 
Seahorse. 
One day prior to analysis, cell cultures were dissociated and seeded 5x104 cells per well onto 24 
well Seahorse XF24 Cell Culture Microplates (Agilent) coated with 0.01% gelatin. On the day of analysis, 
Seahorse XF24 Extracellular Flux Assay (Agilent) was conducted following the manufacturer’s 
instructions. After analysis, cells in the microplates were fixed with 4% PFA in PBS at 4°C overnight. Cells 
were subsequently stained with Hoechst 33342 (Life Technologies) and imaged using EVOS FL Auto Cell 
Imaging System (Life Technologies). The nuclei in two 20X fields of view per well were counted manually 
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and averaged. Raw oxygen consumption rate values were divided by the average cell count for each well 
to obtain the oxygen consumption rate per cell. 
Real Time Quantitative Polymerase Chain Reaction. 
Total RNA was harvested from cell cultures using standard phenol/chloroform isolation with 
TRIzol reagent (Thermo Fisher Scientific). cDNA was obtained by SuperScript III Reverse Transcriptase 
(Thermo Fisher Scientific) according to the manufacturer’s instructions. RT-qPCR was performed on a 
ViiA 7 Real-Time PCR System (Applied Biosystems) with SYBR Green (Thermo Fisher Scientific) chemistry. 
MitoSOX Flow Cytometry. 
Cell cultures in 24 well plates were washed with PBS and dissociated with 0.025% Trypsin-EDTA. 
Trypsin was quenched with 10% FBS in PBS. Cells were washed twice in warm PBS and loaded with 3 μM 
MitoSOX (Invitrogen) at 37°C for 15 minutes in a shaking incubator. Cells were washed twice with PBS 
and resuspended in PBS for immediate analysis by flow cytometry. Data was collected on a CyAn ADP 
high-speed analyzer (Beckman Coulter) and analyzed using FlowJo software (Tree Star). 
Western Blotting. 
Cells were lysed in 2x SDS loading buffer (Bio-Rad). Proteins in cell lysate was separated by SDS-
PAGE and transferred to nitrocellulose membranes. Membranes were cut according to marker 
molecular weight, blocked in 5% milk, and probed with antibody against H3K27Ac (1:1000, Abcam) or β-
Actin (1:2000, Santa Cruz Biotechnology) as a loading control. The target proteins were detected by 
chemiluminescence (ECL, Thermo Fisher Scientific).  
Cardiac Reprogramming Using the icMEF Cell Line. 
The icMEF cell line (Vaseghi et al., 2016) was seeded at a density of 2x104 cells per well in 24 
well plates coated with 0.01% gelatin. The following day, media was changed to iCM media (4:1 
DMEM:M199 with 10% FBS) with 1 g/mL doxycycline. Three days post infection, cells were dissociated 
with 0.025% Trypsin-EDTA, washed and resuspended in PBS. Transduction efficiency was analyzed 
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immediately by flow cytometry for GFP reporter fluorescence. Data was collected on a CyAn ADP high-
speed analyzer (Beckman Coulter) and analyzed using FlowJo software (Tree Star). 
RNA Sequencing. 
RNA was extracted from samples at reprogramming D3 using TRIzol and further purified using 
an RNAeasy kit (Qiagen). Sample RNA integrity number (RIN) was determined by bioanalyzer. All 
samples had RIN above 8 and were further processed. Complementary DNA (cDNA) libraries were 
prepared using a TruSeq Stranded mRNA Library Preparation kit (Illumina). Barcoded Illumina libraries 
were pooled and submitted to the UNC High Throughput Sequencing Facility (HTSF) and sequenced for 
100 base pair (bp) pair-end reads on an Illumina HiSeq 2500. About 6 × 107 100 bp pair-end reads per 
sample were obtained. Sequencing reads with Illumina barcodes removed were received from the HTSF 
in .fastq format. Sequencing quality was checked by FASTQC. The reads were high quality and did not 
require trimming. Raw reads were mapped to the mm10 genome using HISAT2. The raw counts were 
mapped to genes using featureCounts from the SubRead package in R. Then the raw count was divided 
by the length of each genes in kilobase to produce read per kilobase (RPK). Then all the RPK values were 
added and divided by 1 million to produce the scaling factor. The RPK values were divided by the scaling 
factor to produce transcripts per million (TPM) as the final readout for each gene's expression.  For 
differential expression analysis of LacZ vs MGT samples and MGT+shNT vs MGT+shFis1 samples, raw 
counts were inputted into DESeq2 in R and lists of differentially expressed genes (DEG) were obtained 
(False Discovery Rate (FDR) < 0.05, fold change > 1). GO analysis was performed using clusterprofiler. All 
GO terms shown in this study have p value or corrected p value (FDR) < 0.05. Volcano plots were 
generated using the plot function in the DESeq2 package in R. 
Statistical Analyses. 
Where appropriate, values are expressed as the mean ± standard deviation of triplicate 
experiments. Statistical analyses were performed with two-way Student’s T-test or two-way analyses of 
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variance followed by Bonferroni correction. A P value of < 0.05 was considered statistically significant 
(*), a P value of < 0.01 was considered highly significant (**), and a P value of < 0.001 was considered 
strongly significant (***). 
Results 
Reprogramming increases mitochondria. 
Since cardiomyocytes have more mitochondria than fibroblasts, we expect that as we 
reprogram fibroblasts into induced cardiomyocytes (iCMs) they will acquire more mitochondria. To test 
this, we quantified mitochondrial DNA copy number per cell. Mitochondria are unique intracellular 
organelles that inherit and maintain their own genetic material apart from the nuclear genome 
(Friedman and Nunnari, 2014). Mitochondria have a circular 16 kilobase chromosome encoding 13 
genes, 22 tRNA, and 2 ribosomal RNA that is stored in the mitochondrial matrix (Friedman and Nunnari, 
2014). The interconnected mitochondrial network contains multiple copies of the mitochondrial genome 
(Friedman and Nunnari, 2014). Mitochondria typically contain between 1-10 copies of the mitochondrial 
genome (Phillips et al., 2014). As a result, there are many more copies of the mitochondrial genome in a 
cell than the nuclear genome (Friedman and Nunnari, 2014; Memon et al., 2017). Cells may contain 
between 1,000 and 10,000 copies of the mitochondrial genome per cell (Rooney et al., 2015). Cellular 
mitochondrial genome copy number is dependent on cell type and stage of development (Phillips et al., 
2014; Rooney et al., 2015). Quantifying the ratio of mitochondrial genome copies to nuclear genome 
copies is a standard method for estimating cellular mitochondrial content and mitochondrial biogenesis 
(Memon et al., 2017; Phillips et al., 2014). We used qPCR to quantify the copy number of two genes on 
the mitochondrial chromosome (MT-ND2 and MT-CO1) and two genes on a nuclear chromosome 
(PECAM1 and B2M). We then normalized the mitochondrial gene copy number to the nuclear gene copy 
number in order to quantify the number of mitochondrial chromosomes per diploid cell. We found that 
the mitochondrial chromosome copy number of iCMs does not increase compared to unreprogrammed 
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fibroblasts until reprogramming day 21 (Figure 4.1A), coincident with the emergence of spontaneously 
beating iCMs. 
As another technique to quantify cellular mitochondrial content, we measured the intensity of 
MitoTracker Red CMXRos staining. MitoTracker Red CMXRos is a cell permeable dye that is selectively 
retained by polarized mitochondria. We quantified MitoTracker Red CMXRos fluorescence intensity by 
flow cytometry to determine the mitochondrial content of individual cells. Again, we found that the 
cellular mitochondrial content of iCMs was not greater than that of unreprogrammed fibroblasts (Figure 
4.1B). Due to technical difficulties, we were unable to conduct MitoTracker Red CMXRos flow cytometry 
later than D12 of reprogramming. 
Contrary to our expectation, we found that iCMs do not have increased cellular mitochondrial 
content compared to unreprogrammed fibroblasts early in reprogramming. However, we did observe a 
significant increase in cellular mitochondrial content late in reprogramming at the time when 
spontaneously beating iCMs emerged. This increase in mitochondria late in reprogramming is consistent 
with the increased energy demands of a contracting cardiomyocyte. 
Reprogramming increases respiratory capacity. 
Direct cardiac reprogramming is an energetically demanding process. Moreover, cardiomyocyte 
differentiation has been shown to be dependent on cardiac mitochondria maturation (Folmes et al., 
2012; Hom et al., 2011). We therefore expect that reprogramming will increase cellular metabolic 
demands. To examine cellular energy production in reprogramming cells, we profiled mitochondrial 
respiration using Seahorse to measured oxygen consumption rate (Figure 4.2A). Since oxygen 
consumption is proportional to aerobic respiration (Ow et al., 2008; Westermann, 2010), quantifying 
cellular oxygen consumption is a convenient proxy for measuring aerobic respiration. We found that 
reprogramming does not increase base respiration rate compared to unreprogrammed fibroblasts 
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(Figure 4.2B). However, reprogramming does increase the maximum respiratory capacity compared to 
unreprogrammed fibroblasts as early as reprogramming day 8 (Figure 4.2C).  
Inhibiting mitochondrial fission enhances reprogramming. 
Mitochondrial morphology is dynamic, governed by fusion and fission processes. Mfn1, Mfn2, 
and Opa1 regulate mitochondrial membrane fusion, while Fis1 and Drp1 mediate mitochondrial fission 
(Wai and Langer, 2016) (Figure 4.3A). Mitochondrial fusion is required for cardiomyocyte maturation 
during embryonic development (Hom et al., 2011) and Drp1 and Mfn2 are differentially expressed 
during the cardiac differentiation of embryonic stem cells (Chung et al., 2007). We therefore expect that 
inhibiting mitochondrial fission and promoting mitochondrial fusion will enhance direct cardiac 
reprogramming. We knocked down key regulators of mitochondrial dynamics using short hairpin RNA 
(shRNA) interference and found that inhibiting mitochondrial fission through Fis1 or Drp1 knockdown 
enhanced reprogramming (Figure 4.3B and C), while inhibiting mitochondrial fusion through Mfn1, 
Mfn2, or Opa1 knockdown failed to enhance reprogramming (Figure 4.3B).  
Fis1 depletion increases cellular mitochondrial content. 
Inhibiting mitochondrial fission is expected to cause significant changes to mitochondrial 
morphology and function. We next asked if inhibiting mitochondrial fission alters cellular mitochondrial 
content. We found that Fis1 knockdown increases both mitochondrial DNA copy number (Figure 4.4A) 
and cellular mitochondrial content (Figure 4.4B). Given that Fis1 depletion increases cellular 
mitochondrial content, a pivotal question is whether those mitochondria are healthy and functioning or 
unhealthy and defunct. 
Reactive Oxygen Species (ROS) mechanism. 
Studies show that inhibiting key mediators of mitochondrial fission yields unhealthy 
mitochondria and increases the generation of reactive oxygen species (ROS) (Lee et al., 2007; Parone et 
al., 2008). Oxygen is the final electron acceptor in the electron transport chain at Complex IV (West et 
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al., 2011). Reactive oxygen species (ROS) are generated when oxygen accepts electrons early at Complex 
I, II, or III to form superoxide radicals (West et al., 2011). Mitochondria are the primary source of 
intracellular ROS (Suski et al., 2012). ROS are generated by mitochondria of metabolically active cells 
(West et al., 2011), mitochondria with a high membrane potential (Suski et al., 2012), and mitochondria 
with damaged respiratory complexes (Genova et al., 2004; Kurihara et al., 2012). Depletion of Drp1 in 
HeLa cells results in highly fused mitochondrial networks and mitochondrial dysfunction with loss of 
mitochondrial membrane potential, increased ROS generation, reduced mitochondrial respiration, and 
decreased cellular ATP content (Parone et al., 2008). Depletion of Fis1 in HeLa cells causes elongated 
mitochondria, reduced mitochondrial membrane potential, increased ROS generation, and induced 
cellular senescence (Lee et al., 2007). This suggests that our Fis1 knockdown in reprogramming 
fibroblasts may increase mitochondrial ROS generation and intracellular ROS levels.  
Elevated ROS levels have been shown to promote the cardiac differentiation of embryonic stem 
cells through p38 MAPK activation and Mef2c nuclear localization (Crespo et al., 2010; Li et al., 2006). 
Conversely, the addition of free radical scavengers reverses this cardiogenic effect (Bartsch et al., 2011; 
Buggisch et al., 2007; Crespo et al., 2010; Law et al., 2013; Li et al., 2006; Sauer et al., 2000). Increased 
ROS generation induces the gene expression of cardiac transcription factors Gata4 and Mef2c, among 
others (Buggisch et al., 2007; Crespo et al., 2010; Law et al., 2013). Accordingly, we hypothesize that Fis1 
knockdown increases mitochondrial ROS generation and enhances reprogramming through cardiogenic 
ROS signaling (Figure 4.5).  
Inhibiting mitochondrial fission does not increase ROS. 
Since studies show that inhibiting regulators of mitochondrial fission increases ROS generation 
(Lee et al., 2007; Parone et al., 2008), we expected to find that knocking down Fis1 increases 
mitochondrial ROS. However, we did not detect an increase in mitochondrial ROS in Fis1 knockdown 
cells using flow cytometry for MitoSOX staining at 48, 72, or 240 hours post infection with shFis1 
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lentivirus (Figure 4.6A, B, and C). Gene expression of Fis1 is significantly reduced by 24 hours post 
infection with shFis1 lentivirus and is completely abolished by 72 hours (Figure 4.6D).  
ROS do not mediate reprogramming. 
Although we did not detect elevated ROS levels in Fis1 depleted cells (Figure 4.6), ROS are 
volatile and can be difficult to quantify. To directly test the effect of ROS on reprogramming, we treated 
reprogramming iCMs with various concentrations of hydrogen peroxide (H2O2). However, we did not see 
an increase in reprogramming in cells treated with exogenous ROS (Figure 4.7A). This finding indicates 
that ROS signaling does not enhance iCM reprogramming. We then used the ROS scavenger N-
acetylcysteine (NAC) in a rescue experiment. While NAC effectively scavenged ROS (Figure 4.7B), it did 
not reverse the effects of Fis1 knockdown (Figure 4.7C), indicating that Fis1 does not enhance 
reprogramming through ROS signaling. From these findings, we conclude that inhibition of 
mitochondrial fission does not enhance reprogramming through mitochondrial ROS signaling. 
Fis1 depletion increases respiratory capacity. 
Fis1 depletion increases cellular mitochondrial content (Figure 4.4), but as we noted previously 
these mitochondria have the potential to be either healthy and functional or unhealthy and defunct. We 
did not detect elevated ROS generation in Fis1 depleted cells, indicating that the mitochondria of Fis1 
depleted cells are healthy. To confirm that the mitochondria of Fis1 depleted cells are healthy and 
functional we used quantification of mitochondrial oxygen consumption rate using Seahorse to show 
that Fis1 knockdown increases cellular respiration (Figure 4.8A). Both base oxygen consumption rate 
(Figure 4.8B) and maximum oxygen consumption rate (Figure 4.8C) are elevated in Fis1 knockdown 
reprogramming iCMs. These findings indicate that Fis1 depletion results in the accumulation of healthy, 
functional mitochondrial. 
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Overexpression of PGC1α enhances reprogramming. 
As a Fis1-independent approach to increase cellular mitochondrial content, we overexpressed 
PGC1α, a transcriptional co-activator that regulates mitochondrial biogenesis (Jornayvaz and Shulman, 
2010; Vega et al., 2015), in reprogramming cells (Figure 4.9A). Mitochondrial biogenesis through PGC1α 
overexpression enhanced reprogramming efficiency (Figure 4.9B) similarly to Fis1 knockdown (Figure 
4.9C), supporting our hypothesis that Fis1 depletion enhances reprogramming through the 
accumulation of healthy and functional mitochondria.  
Metaboloepigenetic mechanism. 
Healthy, functional mitochondria may enhance reprogramming through a potential mechanism 
involving metabolic intermediates. Many intermediate metabolites function as substrates, energy 
sources, and co-factors for epigenetic modifications (Matilainen et al., 2017). In this way, the 
metabolism regulates transcriptional networks through metabolite-sensitive protein modifications of 
transcriptional regulators (Wellen and Thompson, 2012). These metabolite-sensitive protein 
modifications include acetylation, methylation, glycosylation, and phosphorylation (Wellen and 
Thompson, 2012). For example, the mitochondrial metabolite acetyl-CoA is required as the acetyl group 
donor for histone acetylation, where it masks the positive charge of histone tail lysine and relaxes 
chromatin (Buchakjian and Kornbluth, 2010; Matilainen et al., 2017; Wellen and Thompson, 2012). 
However, acetyl-CoA is generated in a nutrient-dependent manner through glucose metabolism in the 
mitochondria. The mitochondria take up pyruvate generated through glycolysis in the cytoplasm and 
convert it into acetyl-CoA (Buchakjian and Kornbluth, 2010). In the mitochondria, acetyl-CoA enters the 
tricarboxylic acid (TCA) cycle, donating its acetyl group to oxaloacetate (OAA) to form citrate (Buchakjian 
and Kornbluth, 2010). Citrate can be exported from the mitochondria via the mitochondrial citrate 
transporter (CIC) to the cytoplasm (Catalina-Rodriguez et al., 2012). Citrate is converted to back to 
acetyl-CoA and OAA by ATP citrate lyase (ACL) in the cytoplasm or nucleus (Wellen et al., 2009). In the 
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nucleus, histone acetyltransferases require acetyl-CoA as the necessary substrate for histone 
acetylation, which is a transcriptionally permissive epigenetic modification (Buchakjian and Kornbluth, 
2010; Wellen and Thompson, 2012). Histone acetylation is dependent on available levels of the 
metabolic intermediate acetyl-CoA (Wellen and Thompson, 2012). In this way, mitochondrial 
metabolism regulates chromatin dynamics (Matilainen et al., 2017). We therefore propose that Fis1 
depletion generates healthy, functional mitochondria that increase cellular glucose metabolism. This 
increased glucose metabolism elevates acetyl-CoA production in the mitochondria and export to the 
cytoplasm and nucleus for use in histone acetylation enabling gene transcription (Figure 4.10). 
Increasing intracellular acetyl-CoA does not enhance reprogramming. 
To test this hypothesis, we supplemented the cell culture media with metabolic substrates to 
increase intracellular acetyl-CoA during reprogramming. Supplementing iCMs with acetyl-CoA directly in 
the cell culture media did not enhance reprogramming (Figure 4.11A). Sodium acetate and the ketogenic 
amino acids Leucine and Isoleucine are metabolized to acetyl-CoA in the cytoplasm independently of 
mitochondrial activity. Supplementing reprogramming iCMs with sodium acetate or Leucine and 
Isoleucine in the cell culture media did not enhance reprogramming (Figure 4.11B). However, sodium 
acetate media supplementation also did not increase global H3K27ac (Figure 4.11C), indicating that 
media supplementation may not be an effective method of increasing the intracellular acetyl-CoA pool. 
Proliferation mechanism. 
Inhibiting cellular proliferation has been shown to enhance reprogramming (Liu et al., 2017a). 
We also have used Mitomycin C (MMC) to arrest cellular proliferation and have confirmed that 
inhibiting proliferation enhances reprogramming (Figure 4.12A and B). Lee et al. show that Fis1 
depletion in HeLa cells induces mitochondrial elongation, triggering cell cycle arrest and cellular 
senescence (Lee et al., 2007). We too have observed reduced proliferation in Fis1 knockdown cell 
cultures. We therefore hypothesized that Fis1 knockdown enhances reprogramming through inhibiting 
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proliferation. We used shRNA knockdown of Cyclin D1 (shCcnd1) to override the cell cycle and drive 
cellular proliferation. We expected that Cyclin D1 overexpression would reverse the effect of Fis1 
knockdown if indeed Fis1 knockdown enhances reprogramming through cell cycle arrest. However, we 
found that simultaneous knockdown of Cyclin D1 and Fis1 does not reduce reprogramming (Figure 
4.12C), indicating that the depletion of Fis1 enhances reprogramming through a mechanism that is 
independent of the cell cycle. 
Timing and duration of Fis1 knockdown. 
We attempted to identify the temporal window for the maximum efficacy of Fis1 knockdown. To 
do this, we knocked down Fis1 by introduction of shFis1 lentivirus at different timepoints during the 
reprogramming process. Fibroblasts were infected with shFis1 lentivirus before introduction of the 
reprogramming factors (D-1) or at days subsequently to the reprogramming factors (D1, D3, or D5). All 
conditions were analyzed by flow cytometry for cardiac marker cTnT at reprogramming D11 (Figure 
4.13A). We found that early Fis1 knockdown gives the highest reprogramming efficiency (Figure 4.13B). 
We then examined the duration of Fis1 knockdown on reprogramming efficiency. We set up an 
experiment where reprogramming iCMs experienced Fis1 knockdown for a 6-day period. The early 
knockdown condition was infected with shFis1 lentivirus on D1 of reprogramming and analyzed on D7. 
The late condition was infected with shFis1 lentivirus on D5 of reprogramming and analyzed on D11. A 
third condition was infected with shFis1 lentivirus early on D1 of reprogramming but analyzed on D11 
with the late condition (Figure 4.14A). We found that 6 days of Fis1 depletion was insufficient to 
enhance reprogramming by D7 (Figure 4.14B). However, 6 days of Fis1 depletion did minimally enhance 
reprogramming if it was administered late at D5 (Figure 4.14B). We conclude that Fis1 knockdown is 
most effective when Fis1 is depleted at an early time (Figure 4.13B and 4.14B) and for an extended 
duration (Figure 4.14B). 
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Reprogramming factor expression. 
We asked whether Fis1 knockdown increased the expression of Mef2c, Gata4, and Tbx5 from 
the polycistronic MGT reprogramming factor cocktail retrovirus. We used PCR primers for total 
transcription factor expression from within the coding region and endogenous transcription factor 
expression from the 3’ untranslated region (UTR). Retroviral transcription factor expression was 
calculated as the difference between total transcription factor expression minus endogenous 
transcription factor expression, since the retroviral transcription factors were cloned from cDNA and 
thus lack the endogenous 3’ UTR. We found that Fis1 knockdown increases retroviral expression of 
Mef2c (Figure 4.15A) but not Gata4 or Tbx5 (Figure 4.15B and C). Wang et al. showed that the optimal 
stoichiometry of Mef2c, Gata4, and Tbx5 transcription factor expression for reprogramming requires 
more Mef2c than Gata4 or Tbx5 (Wang et al., 2015a). We found that Fis1 knockdown does not increase 
endogenous transcription factor expression (Figure 4.15D-F). 
RNA sequencing.   
We conducted bulk RNA sequencing of Fis1 knockdown verses non-targeting control in both 
MGT infected iCMs and LacZ infected control fibroblasts. We found that few genes are differentially 
upregulated by Fis1 knockdown during reprogramming (Figure 4.16A). This was not enough to give 
meaningful gene ontology analysis results (Figure 4.16B). The transcriptional changes caused by 
reprogramming (MGT vs LacZ) are greater than those caused by inhibiting mitochondrial fission (shFis1 
vs shNT) (Figure 4.16C and D). We conclude that Fis1 knockdown has minimal effect on gene expression. 





Figure 4.1. Direct cardiac reprogramming increases mitochondria late in reprogramming. A) Cellular 
mitochondrial DNA content quantified by qPCR and expressed as the ratio of mitochondrial gene copies 
to nuclear gene copies. Freshly isolated neonatal murine cardiac fibroblasts were infected with either 
MGT polycistronic reprogramming cocktail retrovirus (iCMs) or LacZ control retrovirus (Fibroblasts). B) 
Cellular mitochondrial content quantified by flow cytometry for MitoTracker Red CMXRos and expressed 




Figure 4.2. Direct cardiac reprogramming increases respiratory capacity. A) Oxygen consumption rate 
quantified by Seahorse. Freshly isolated neonatal murine cardiac fibroblasts were infected with either 
MGT polycistronic reprogramming cocktail retrovirus (iCMs) or LacZ control retrovirus (Fibroblasts) at 
D0. B) Baseline oxygen consumption rate of cells from (A). C) Maximum oxygen consumption rate of 




Figure 4.3. Inhibiting mitochondrial fission enhances reprogramming. A) Mitochondrial morphology is 
governed by fission which is regulated through Drp1 and Fis1 and by fusion which is regulated through 
Mfn1, Mfn2, and Opa1. B) Reprogramming efficiency quantified by flow cytometry for cTnT at 
reprogramming D10 and expressed as the percentage of cTnT+ cells. Freshly isolated neonatal murine 
cardiac fibroblasts were infected with MGT polycistronic reprogramming cocktail retrovirus at D0 and 
shRNA lentiviruses at D1. Non-targeting shRNA (shNT) was used as a negative control. C) Cardiac marker 
gene expression quantified by RTqPCR at reprogramming D8. Freshly isolated neonatal murine cardiac 
fibroblasts were infected with MGT polycistronic reprogramming cocktail retrovirus at D0 and shRNA 
lentivirus a D1.  
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Figure 4.4. Inhibiting mitochondrial fission increases mitochondria. A) Cellular mitochondrial DNA 
content at reprogramming D10 quantified by qPCR and expressed as the ratio of mitochondrial gene 
copies to nuclear gene copies. Freshly isolated neonatal murine cardiac fibroblasts were infected with 
MGT polycistronic reprogramming cocktail retrovirus (iCM) or LacZ control retrovirus (Fibroblasts) at D0 
and shRNA lentivirus at D1. Fis1 knockdown lentivirus (shFis1); non-targeting negative control lentivirus 
(shNT). B) Cellular mitochondrial content quantified by flow cytometry for MitoTracker Red CMXRos at 
D10 Freshly isolated neonatal murine cardiac fibroblasts were infected with MGT polycistronic 
reprogramming cocktail retrovirus at D0 and shRNA lentivirus at D1. C) Quantification of MitoTracker 





Figure 4.5. Proposed reactive oxygen species (ROS) signaling pathway. Mitochondria generate 
superoxide from electron transport chain function. Superoxide induces the phosphorylation and 
activation of p38 MAPK which in turn phosphorylates the transcription factor Mef2c resulting in its 




Figure 4.6. Inhibiting mitochondrial fission does not generate ROS. Mitochondrial ROS quantified by 
flow cytometry for MitoSOX at A) 48 hours, B) 72 hours, and C) 240 hours post shFis1 lentivirus infection 
in freshly isolated neonatal murine cardiac fibroblasts. D) Fis1 gene expression quantified by RTqPCR at 




Figure 4.7. ROS do not mediate reprogramming. A) Reprogramming efficiency quantified by flow 
cytometry for the cardiac reporter αMHC-GFP fluorescence. The icMEF cell line was treated with 
doxycycline to induce reprogramming and varying concentrations of hydrogen peroxide (H2O2) for 3 
days. B) Cellular ROS quantified by flow cytometry for ROS indicator dichlorofluorescin diacetate (DCF-
DA). Freshly isolated neonatal murine cardiac fibroblasts were treated with 10 mM ROS scavenger N-
acetylcysteine (NAC), 10 μM redox cycling quinone (DMNQ), or both for 24 hours. C) Reprogramming 
efficiency quantified by flow cytometry for the cardiac marker cTnT at D11. Freshly isolated neonatal 
murine cardiac fibroblasts were infected with MGT polycistronic reprogramming cocktail retrovirus at 
D0 and shRNA lentivirus at D1 with or without 10 mM ROS scavenger N-acetylcysteine (NAC) for 10 
days. Media containing NAC was buffered with NaOH and HCl to pH 8.29. Cell culture media was pH 




Figure 4.8. Inhibiting mitochondrial fission further increases respiratory capacity. A) Oxygen 
consumption rate quantified by Seahorse at reprogramming D12. Freshly isolated neonatal murine 
cardiac fibroblasts were infected with either MGT polycistronic reprogramming cocktail retrovirus (iCM) 
or LacZ negative control retrovirus (Fibroblasts) at D0 and shRNA lentivirus at D1. Fis1 knockdown 
lentivirus (shFis1); non-targeting negative control lentivirus (shNT). B) Baseline oxygen consumption rate 
of cells from (A). C) Maximum oxygen consumption rate of cells from (A) after mitochondrial uncoupling 
by FCCP.   
87 
 
Figure 4.9. Overexpression of PGC1α enhances reprogramming. A) PGC1α gene expression quantified 
by RTqPCR at D3 post infection. Mouse embryonic fibroblasts were infected with PGC1α overexpression 
lentivirus or control GFP overexpression lentivirus at D0. B) Reprogramming efficiency quantified by flow 
cytometry for cardiac marker cTnT at reprogramming D10 Freshly isolated neonatal murine cardiac 
fibroblasts were infected with MGT polycistronic reprogramming cocktail at D0 and PGC1α or GFP 
overexpression lentivirus at D1. C) Reprogramming efficiency quantified by flow cytometry for cardiac 
marker cTnT at reprogramming D11. Freshly isolated neonatal murine cardiac fibroblasts were infected 
with MGT polycistronic reprogramming cocktail at D0 and shRNA lentivirus at D1. Fis1 knockdown 




Figure 4.10. Proposed metaboloepigenetic mechanism. Mitochondrial glucose metabolism generates 
acetyl-CoA inside the mitochondria. The tricarboxylic acid (TCA) cycle produces citrate from acetyl-CoA 
and oxaloacetate (OAA). Citrate can then be exported from the mitochondrial to the cytoplasm by the 
mitochondrial citrate transporter (CIC). In the cytoplasm or nucleus, ATP citrate lyase (ACL) converts 
citrate back into acetyl-CoA and OAA. In the nucleus, acetyl-CoA provides the necessary substrate for 




Figure 4.11. Increasing intracellular acetyl-CoA does not enhance reprogramming. A) Reprogramming 
efficiency quantified by flow cytometry for cardiac marker cTnT at reprogramming D9. Freshly isolated 
neonatal murine cardiac fibroblasts were infected with MGT polycistronic reprogramming cocktail 
retrovirus at D0 and varying concentrations of acetyl-CoA at D2. B) Reprogramming efficiency quantified 
by flow cytometry for cardiac marker cTnT at reprogramming D10. Freshly isolated neonatal murine 
cardiac fibroblasts were infected with MGT polycistronic reprogramming cocktail retrovirus at D0 and 
shRNA lentivirus with or without 1 mM sodium acetate or 10 mM ketogenic amino acids at D1 for 4 
days. Fis1 knockdown lentivirus (shFis1); non-targeting negative control lentivirus (shNT). C) Histone 3 
Lysine 27 acetylation (H3K27ac) quantified by western blot at D5. Freshly isolated neonatal murine 
cardiac fibroblasts were infected with MGT polycistronic reprogramming cocktail retrovirus at D0 and 




Figure 4.12. Inhibiting mitochondrial fission does not enhance reprogramming through cellular 
senescence. Reprogramming efficiency quantified by flow cytometry for A) αMHC-GFP cardiac reporter 
fluorescence and B) cardiac marker cTnT at reprogramming D10. The MEF-T cell line was infected with 
MGT polycistronic reprogramming cocktail retrovirus at D0 and treated with 10 μg/mL mitomycin C 
(MMC) for 2.5 hours at D2. C) Reprogramming efficiency quantified by flow cytometry for cardiac 
marker cTnT at reprogramming D11. Freshly isolated neonatal murine cardiac fibroblasts were infected 
with MGT polycistronic reprogramming cocktail retrovirus at D0 and shRNA lentivirus at D1. Fis1 





Figure 4.13. Timing of mitochondrial fission inhibition. A) Schematic of experimental design. Freshly 
isolated neonatal cardiac fibroblasts were infected with MGT polycistronic reprogramming cocktail 
retrovirus at D0 and shRNA lentivirus at D-1, D1, D3, or D5. Fis1 knockdown lentivirus (shFis1); non-
targeting control lentivirus (shNT). Reprogramming efficiency was quantified by flow cytometry at D10 
(D-1) or D11 (D1, D3, D5). B) Reprogramming efficiency quantified by flow cytometry for cardiac marker 




Figure 4.14. Duration of mitochondrial fission inhibition. A) Schematic of experimental design. Freshly 
isolated neonatal cardiac fibroblasts were infected with MGT polycistronic reprogramming cocktail 
retrovirus at D0 and shRNA lentivirus at D1 or D5. Fis1 knockdown lentivirus (shFis1); non-targeting 
control lentivirus (shNT). Reprogramming efficiency was quantified by flow cytometry at D7 or D11. B) 




Figure 4.15. Reprogramming factor expression. A) Retroviral Mef2c gene expression quantified by 
RTqPCR at reprogramming D3. Retroviral gene expression was calculated as the difference between 
total gene expression and endogenous gene expression. B) Retroviral Gata4 gene expression. C) 
Retroviral Tbx5 gene expression. D) Endogenous Mef2c gene expression quantified by RTqPCR at 
reprogramming D3. Endogenous gene expression was detected by qPCR primers specifically designed for 




Figure 4.16. RNA sequencing. A) Differential gene expression of Fis1 knockdown and non-targeting 
control during MGT reprogramming. B) Gene ontology pathway analysis. C) Differential gene expression 
of MGT reprogramming iCMs and LacZ control infected fibroblasts with Fis1 knockdown. D) Gene 




We have shown that inhibiting mitochondrial fission enhances reprogramming efficiency and 
increases cellular mitochondrial content and respiration rate. Overexpressing PGC1α to drive 
mitochondrial biogenesis similarly enhances reprogramming, confirming that the effect on 
reprogramming is due to increased mitochondrial content in reprogramming cells. The greatest 
enhancement of reprogramming occurs when Fis1 is depleted for the maximum time period during 
reprogramming. Future experiments will repeat these time course studies for PGC1α overexpression to 
determine whether the effect of mitochondrial biogenesis is similarly duration dependent. Intriguingly, 
Fis1 depletion does not affect early reprogramming events. Our RNA sequencing results from 
reprogramming D3 showed minimal changes in gene expression from Fis1 depletion. Moreover, flow 
cytometry at reprogramming D7 did not show increased expression of cardiac marker cTnT in Fis1 
depleted iCMs. 
We have shown that inhibiting mitochondrial fission enhances reprogramming, but the 
mechanism remains elusive. We demonstrated that Fis1 depletion does not enhance reprogramming 
through reactive oxygen species signaling. We also demonstrated that Fis1 depletion does not enhance 
reprogramming by triggering cellular senescence. Our proposed metaboloepigenetic hypothesis requires 
further testing. Direct measurement of the intracellular acetyl-CoA pool is required to validate our 
attempts to increase intracellular acetyl-CoA through metabolic substrate supplementation in the cell 
culture media.  
We suggest that direct cardiac reprogramming is energetically expensive process, involving the 
dismantling of the fibroblast program and establishment of the new cardiomyocyte identity. We 
propose that Fis1 depletion’s enhancement of reprogramming is not cardiac specific. Rather, Fis1 
depletion creates a larger, more efficient mitochondrial network which provides the energy for cell fate 
conversions. If this hypothesis is correct, we would expect Fis1 depletion to similarly enhance the direct 
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS 
Applications of Our Inducible Fibroblast Cell Lines 
All cell lines and constructs described in Chapter 2 were made available to the research 
community. As of writing, we have freely shared these reagents with 11 labs in 4 countries (Table 5.1). 
These cell lines have contributed to research in our lab and others. Two labs are currently working 
toward publication of projects based on the cell line. Dr. Samantha Morris at Washington University 
School of Medicine in St. Louis is performing linage tracing during cardiac reprogramming using the 
icMEF cell line. This project is still in its preliminary stages. Dr. Alexandre Colas at Sanford Burnham 
Prebys Medical Discovery Institute is wrapping up a project identifying transcription factors as barriers 
to direct cardiac reprogramming. A manuscript for this project is in preparation for publication.  
We ourselves have used the cell lines in multiple publications. We used the icMEF cell line to 
conduct a loss of function screen for splicing factors during reprogramming (Liu et al., 2017a). Single cell 
RNA sequencing indicated that GO terms associated with mRNA splicing and mRNA processing were 
downregulated during reprogramming (Liu et al., 2017a). We accordingly conducted a loss of function 
screen in the icMEF cell line using short hairpin RNA to target 26 splicing factors that represent the most 
common splicing factor families (Liu et al., 2017a). This screen identified top candidate Ptbp1 as a 
significant barrier to reprogramming. Further studies revealed that silencing Ptbp1 during MGT 
reprogramming shifts alternative splicing patterns from that of a cardiac fibroblast to that of a 
cardiomyocyte (Liu et al., 2017a). We used the MEF-T cell line extensively to compare 2A self-cleaving 
peptide efficiency (Liu et al., 2017b). This project characterized the gene expression levels of 
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Table 5.1. Research groups using the MEF-T and icMEF cell lines.  
 
Principle Investigator University Country Department Cell Lines
Benzhi Cai Harbin Medical University China Department of Pharmacology MEF-T, icMEF
V.M. Christoffels University of Amsterdam Netherlands Department of Anatomy, Embryology, and Physiology MEF-T, icMEF
Zhiyong Lei University Medical Center Utrecht Netherlands Division of Heart and Lungs, Department of Cardiology MEF-T
Thierry Pedrazzini Lausanne University Medical School Switzerland Division of Hypertension MEF-T
Alexandre Colas Sanford Burnham Prebys Medical Discovery Institute USA Development, Aging, and Regeneration Program MEF-T, icMEF
Chuanxi Cai Albany Medical College USA Center for Cardiovascular Sciences icMEF
Jeffery Molkentin University of Cincinnati USA Cincinnati Children's Hospital Medical Center icMEF
Kai Wang Baylor College of Medicine USA Department of Surgery and Medicine icMEF
Rajan Jain University of Pennsylvania USA Department of Medicine icMEF
Samantha A. Morris Washington University School of Medicine in St. Louis USA Departments of Developmental Biology and of Genetics icMEF




Although exciting advances are being made in direct cardiac reprogramming using chemical 
cocktails (Cao et al., 2016; Fu et al., 2015), cell fate reprogramming is typically accomplished through the 
forced expression of cell lineage transcription factors. This transcription factor-driven cell fate 
reprogramming depends on chromatin accessibility for transcription factor-DNA interactions (Luna-
Zurita and Bruneau, 2013). Chromatin structure is dynamic, alternating between an open, accessible 
state (which is transcriptionally permissive) and a closed, inaccessible state (which is transcriptionally 
repressive) (Luna-Zurita and Bruneau, 2013). These changes in chromatin structure are regulated by 
post-translational histone modifications – methylation, acetylation, and ubiquitination – which are in 
turn catalyzed by chromatin-modifying enzymes (Luna-Zurita and Bruneau, 2013). 
Given that chromatin structure regulates transcription factor accessibility, it may be possible to 
prime cells for more efficient and complete reprogramming by altering the chromatin landscape. 
However, the role of most chromatin-modifying enzymes in direct cardiac reprogramming is yet 
undetermined. Moreover, several recent studies show conflicting results, indicating hidden 
complexities. As described in Chapter 3, we performed a short hairpin RNA interference loss-of-function 
screen of 35 epigenetic modifiers (Zhou et al., 2016). Silencing 11 of the 35 epigenetic regulators 
reduced reprogramming efficiency to varying degrees, identifying factors that are required for 
reprogramming. These include the H3K4me3/2 reader protein Ing1 and H3K4me3/2 demethylase Plu1. 
Silencing other factors enhanced reprogramming efficiency, identifying factors that function as barriers 
to reprogramming. These include the histone acetyltransferases Myst2 and Myst3, the H3K4 
demethylase Smcx, and the PRC1 component Bmi1. We recently performed another loss-of-function 
screen that targeted an additional 25 epigenetic factors involved in chromatin remodeling as well as 
RNA splicing factors (Zhou et al., 2018). We found that silencing Bcor, which is involved in the BCOR 
complex superfamily, or Stag2, which is involved in the cohesin complex, enhanced reprogramming, 
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indicating that Bcor and Stag2 function as barriers to reprogramming. Silencing the H3K4 
methyltransferases Mll1, Mll2, or Mll5 reduced reprogramming efficiency, highlighting the importance 
of H3K4 methylation in reprogramming. Liu et al., however, performed a gain-of-function screen of 47 
epigenetic and transcription factors and identified the H3K4 methyltransferase Mll1 as a barrier to 
reprogramming (Liu et al., 2016a). Contrary to our findings, Liu et al., showed that inhibiting Mll1 
enhances reprogramming (Liu et al., 2016a).  Similarly, Dal-Pra et al. and Hirai et al. demonstrate that 
inhibiting Ezh2 activity enhances reprogramming (Dal-Pra et al., 2017; Hirai and Kikyo, 2014), but we 
were unable to replicate their findings in our experimental system (Chapter 3). 
To elucidate the effect of chromatin state on direct cardiac reprogramming, we propose the use 
of newly emergent technology such as SNARE-seq (Chen et al., 2019), scCAT-seq (Liu et al., 2019), 
Paired-seq (Zhu et al., 2019), or ASTAR-seq (Xing et al., 2019) all of which sequence chromatin 
accessibility and RNA expression simultaneously at single cell resolution. These techniques would 
identify subpopulations of reprogramming cells with different chromatin accessibility profiles and 
overlay these findings with our previously identified subpopulations of reprogramming and refractory 
cells (Liu et al., 2017a). Such an approach would allow us to distinguish which epigenetic changes 
correlate with successfully reprogrammed cells. Performing simultaneous chromatin accessibility and 
RNA transcription sequencing over a time course would allow us to reconstruct the epigenetic changes 
as they occur sequentially during reprogramming and identify potential chromatin manipulations to 
enhance reprogramming efficiency. To elucidate the roles of chromatin-modifying enzymes in direct 
cardiac reprogramming, we propose the use of our icMEF inducible fibroblast cell line to screen libraries 
of small molecule inhibitors for epigenetic factors. Our icMEF cell line is especially designed to facilitate 




The preliminary metaboloepigenetic studies related in Chapter 4 are as yet insufficient to draw a 
final conclusion regarding the role of acetyl-CoA in direct cardiac reprogramming. We propose to 
directly measure intracellular acetyl-CoA pool in order to validate our methods for increasing 
intracellular acetyl-CoA through cell culture media supplementation. If, however, acetyl-CoA is not the 
metabolite linking Fis1 depletion and enhanced reprogramming, there are other potential 
metaboloepigenetic pathways. Many metabolites function as epigenetic co-factors (Matilainen et al., 
2017). S-adenosyl methionine (SAM) is a by-product of mitochondrial metabolism that also serves as the 
methyl group donor for histone and DNA methylation (Matilainen et al., 2017). Mitochondria also 
regulate the abundance of flavin adenine dinucleotide (FAD), which is an essential co-factor for lysine 
demethylases (Matilainen et al., 2017). The mitochondrial TCA cycle also generates α-ketoglutarate, 
which is an essential co-factor for histone lysine demethylases and DNA demethylases (Matilainen et al., 
2017).  
Fis1 Depleted iCM Mitochondrial Morphology 
Inhibiting mitochondrial fission is expected to have significant effects on mitochondrial 
morphology, but as yet we have not conducted any mitochondrial imaging. We suggest the use of 
confocal microscopy z-stacks to reconstruct the volume of the mitochondrial compartment in Fis1 
depleted and control cells. Mitochondrial morphology will be quantified using aspect ratio (roundness vs 
elongation) and form factor (degree of branching). Additionally, imaging will be conducted co-staining 
with TOM-20 antibody to label all mitochondria and MitoTracker CMXRos dye to label polarized 
mitochondria. This will allow us to distinguish the healthy mitochondria within the total mitochondrial 
population of a cell and further confirm the health of mitochondria in Fis1 depleted cells. 
Furthermore, we would like to see the comparison of mitochondrial compartment volume and 
morphology between neighboring cTnT+ iCMs and cTnT- reprogramming resistant iCMs. Since only a 
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fraction of fibroblasts infected with the MGT reprogramming retrovirus express cTnT, some currently 
undiscovered barrier inhibits reprogramming iCMs from completely converting. We are curious to 
compare mitochondria between successfully reprogrammed cTnT+ iCMs and incompletely 
reprogrammed cTnT- cells. 
Fis1 Depleted iCM Maturation  
While we have successfully demonstrated that Fis1 depletion enhances reprogramming 
efficiency, we have not yet examined its effect on iCM maturation by comparing the Fis1 depleted iCM 
phenotype to neonatal and adult cardiomyocytes. Gene set enrichment analysis indicates that in vitro 
reprogrammed iCMs are more similar to mature adult cardiomyocytes than to neonatal cardiomyocyte 
and that reprogramming iCMs gain adult cardiomyocyte transcriptional features rapidly during 
reprogramming (Zhou et al., 2017b). We propose to examine whether Fis1 depletion promotes 
acquisition of a still more mature adult cardiomyocyte phenotype by repeating our mitochondrial 
quantification, Seahorse, and RNA sequencing to compare control iCMs and Fis1 depleted iCMs with 
neonatal and adult murine cardiomyocytes. 
Cardiac Specificity of Fis1 Depletion 
Since mature, adult cardiomyocytes have such unique metabolic demands and mitochondrial 
capacity, it is tempting to think about mitochondria and their role in direct cardiac reprogramming in a 
cardiac specific context. However, the effect of Fis1 depletion on cell fate reprogramming outcomes is 
not necessarily cardiac specific. Cell fate conversions are energetically expensive processes, requiring 
the dismantling of the starting cell identity and establishment of the new cell fate. Fis1 depletion 
increases cellular mitochondrial content and respiratory capacity, but rather than being specific to a 
mature cardiomyocyte fate, this expanded mitochondrial network may provide the energy to power cell 
fate conversions broadly. To test this hypothesis, we propose to deplete Fis1 in other cell fate 
reprogramming processes, for example direct conversion of fibroblasts to neurons (Vierbuchen et al., 
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2010) or hepatocytes (Huang et al., 2011; Sekiya and Suzuki, 2011). We expect that Fis1 depletion will 
enhance the cell fate reprogramming of fibroblasts into cardiomyocytes, neurons, hepatocytes, and 
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